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Pancreatic ductal adenocarcinoma (PDAC) represents 85% of pancreatic cancers.
With early stage diagnosis, PDAC has a relative five-year survival rate of 34% but drops
to 3% with metastasis. There is a lack of distinct symptoms and dependable biomarkers
which delays diagnosis, leading to poor prognosis. Angiopoietin-like 4 (ANGPTL4)
protein has been indicated in the progression of several types of aggressive cancer.
ANGPTL4 is natively present in two fragments, an amino-terminus coiled-coil domain
(nANGPTL4) and a carboxy-terminus fibrinogen-like domain (cANGPTL4), which have
demonstrated diverse biological functions. Biochemical studies have been performed but
a full structural understanding of functions and interactions is not available.
Overexpression of ANGPTL4 has been found in pancreatic tumor tissues of all
stages. Its complexity and ability to target various cancer cell microenvironments,
endothelial cells, and metabolic activities makes it a prime candidate for therapeutic
intervention. The goal of this research was to acquire knowledge of cANGPTL4’s
molecular role in PDAC progression by comprehending its mechanisms of action through
structure-function studies that would enable the development of therapeutics. In order to
accomplish this goal, differential expression of hypoxia induced ANGPTL4 was
compared
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Chapter 1

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive form of
pancreatic cancer that is accompanied by a low probability of survival (Noone et al.,
2017). The American Cancer Society (ACS) estimates that approximately 45,750 people
will succumb to this disease in 2019. PDAC has a relative five-year survival rate of 34%
with early stage diagnoses that drops to 3% with metastasis (Noone et al., 2017). The
deficiency of a meticulous diagnostic exam makes early stage diagnoses a serious
challenge. A poor prognosis is also due to a lack of comprehension of PDAC’s complex
molecular processes. This complexity is due to intrinsic factors, such as genetic and
epigenetic heterogeneity within a tumor, and extrinsic factors, such as tumor
microenvironment. These factors result in large variations in the degree to which cancer
cells invade and metastasize (Gupta and Massagué, 2006; Prasetyanti and Medema, 2017;
Assenov et al., 2018).
Angiopoietin-like 4 (ANGPTL4) has been indicated in the progression of several
types of aggressive cancer (Padua et al., 2008; Hu et al., 2011; Nakayama et al., 2011;
Kirbya et al., 2016), but its structure and function are poorly understood (Zhu et al.,
2012; Tan et al., 2012). This lack of knowledge impedes the comprehension of this
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protein’s basic biology. PDAC’s high mortality rate is due to its inclination to
metastasize. Several studies found increased expression levels of ANGPTL4 in excised
pancreatic tumor cells, and studies have suggested potential roles of this protein’s
carboxy-terminal fibrinogen-like domain in tumor progression (Tan et al., 2012). For
example, the carboxy-terminal fibrinogen-like domain of ANGPTL4 has been shown to
facilitate metastasis by disrupting endothelial barrier integrity when interacting with
integrin b1, VE-cadherin, and claudin-5. The binding affinity of these proteins was
previously determined by surface plasmon resonance (SPR), but the interacting residues
are not known (Huang et al., 2011). Furthermore, it is unknown if other biological
molecules, such as carbohydrates or fatty acids, bind to ANGPTL4’s carboxy-terminal
domain.
ANGPTL4 is natively present as a full-length protein and in two fragments, an
amino-terminus coiled-coil domain (nANGPTL4) and a carboxyl-terminus fibrinogenlike domain (cANGPTL4), which have shown diverse biological functions (Lei et al.,
2011). cANGPTL4 has been associated with angiogenesis, cancer cell invasion, cell
migration, endothelial cell functions, and cell adhesion (Tan et al., 2012). Biochemical
studies have been performed but a full structural understanding of functions and
interactions is not available. ANGPTL4’s complexity and ability to target various cancer
cell microenvironments, endothelial cells, and metabolic activities makes it a prime
candidate for therapeutic intervention (Tan et al., 2012). The function of a protein can be
inferred from its structure, and changes in protein conformations or binding to other
proteins can lead to altered functions. The goal of this research was to acquire
knowledge of cANGPTL4’s molecular role in PDAC progression by comprehending its
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mechanisms of action through structure-function studies that would enable the
development of therapeutics. The three specific aims of this study to accomplish this
goal were:
> Aim 1: To understand how cANGPTL4 expression drives malignant phenotype.
> Aim 2: To extend the existing structure-function studies from bacterially
produced to structure-function studies associated with human cancer cells.
> Aim 3: To determine specific residues of cANGPTL4 that interact with binding
partners.
Differential expression of certain proteins has been correlated to phenotypic
characteristics such as invasion, migration, tumorigenesis, and chemotherapeutic
resistance (van der Horst et al., 2012). The observation that ANGPTL4 is highly
expressed in multiple carcinomas and cell lines raised some interesting questions. As
part of this study we explore:
> Is ANGPTL4 differentially expressed in pancreatic cancer cell lines? If so, is
there a correlation between expression levels and phenotypic characteristics of
pancreatic cancer cells?
> Are hypoxic environmental conditions necessary for expression and secretion of
ANGPTL4 cancer cells?
> How does the expression levels of ANGPTL4 in pancreatic cancer cell lines
compare to expression levels in breast cancer cell lines?
> Which isoforms of ANGPTL4 protein are secreted in pancreatic cancer cells?
We discovered that hypoxia-induced expression of ANGPTL4 was highest in Panc-1
and MDA-MB231 cell lines. Cells from both lines are considered to have highly
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invasive phenotypes. Using immunofluorescence and confocal imaging, colocalization
of cANGPTL4 and integrin β1 was seen in Panc-1 cells. Previous research revealed
cANGPTL4 interacts with integrin β1, resulting in reduced cell-cell contact mediating
metastasis. Finally, three high-resolution crystallographic structures were determined of
cANGPTL4, each in complex with a different ligand. Palmitic and myristic acid were
shown to bind to cANGPTL4, and the same binding site was also found to bind glycerol.
This binding was observed in both crystallographic derived structures and inferred from
cell culture assays. The binding of palmitic acid to cANGPTL4 was further supported by
thermal denaturation assay. Results indicated a Kd ranging from 0.77 to 1.3 µM at a
protein concentration of 1.0 µM, which is well within expected physiological
concentrations (Abdelmagid et al., 2015). Furthermore, immunofluorescence and
confocal imaging studies showed that the cANGPTL4/fatty acid complex were taken up
by the cell.
The binding of cANGPTL4 to glycerol, myristic acid, and palmitic acid points to
possible mechanisms for function for cANGPTL4. Unliganded cANGPTL4 binds to cell
surface proteins, while the cANGPTL4/fatty acid complex does not, but is instead taken
up by the cell. cANGPTL4 may offer a route for the delivery of drug molecules into
cancer cells. Whether the fatty acid transport is just a means of supplying energy to the
cell, or if it also includes a signaling function, remains to be determined.
We present these findings here.
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Chapter 2

Background and Significance
2.1 The Pancreas
The pancreas is a retroperitoneal appendage with both exocrine and endocrine
functions. A healthy pancreas appears lobular and yellow in color. This organ is divided
into four sections: head, neck, body, and tail (Figure 1). The widest part is the pancreatic
head, and it is positioned in the C-loop of the duodenum. The protrusion from the lower
portion of the head of the pancreas is the uncinate process. It lies between the superior
mesenteric vessels and the aorta. The pancreatic head and body are attached by a
pancreatic neck that is positioned in front of the portal vein. Extending from the neck to
the left is the body of the pancreas, which narrows into a tapering tail. This tail continues
in the direction of the splenic hilum. A major pancreatic duct joins the pancreas to the
common bile duct, and both ducts drain into the major duodenal papilla. It drains
exocrine secretions as it runs across the pancreas from tail to head. An accessory
pancreatic duct supplies additional drainage in some individuals. This duct drains
separately into the duodenum at the minor duodenal papilla (Longnecker et al., 2018).
Similar to the gastrointestinal tract, blood supply to the pancreas comes from
several main arteries. The celiac trunk and superior mesenteric artery supply blood to the
pancreas. From the celiac trunk, the common hepatic artery branches into the hepatic and
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gastroduodenal artery. The gastroduodenal artery branches into the anterior and posterior
pancreaticoduodenal arteries that supply blood to the head of the pancreas. From the
celiac trunk, the splenic artery produces the dorsal pancreatic artery, pancreatic magna,
and caudal pancreatic artery. These supply blood to the pancreatic body and tail. Vessels
of the extensive lymphatic system travel alongside the arteries in the pancreas
(Longnecker et al., 2018).

Figure 2.1: Anatomy of human pancreas, with focus on the endocrine and exocrine cells.
Image from ACS at https://www.cancer.org/cancer/pancreatic-cancer/about/what-ispancreatic-cancer.html.
The pancreas is both an exocrine and endocrine gland. A majority of the pancreas
consists of exocrine, or acinar, cells which form clusters called acinus. Acinar cells
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produce, store, and secrete various pancreatic enzyme proteins necessary for the digestion
of nutrients (Figure 2) (Gorelick et al., 2018). Digestive enzymes such as amylase and
lipase are active upon secretion since they are not known to damage pancreatic cells.
Pancreatic proteases, such as trypsin and chymotrypsin, synthesized by acinar cells are
stored as inactive proenzymes (trypsinogen and chymotrypsinogen) in zymogen granules
to prevent pancreatic cellular damage (Pandol, 2011). Once stimulated by acetylcholine
(ACh), cytosolic Ca2+ concentrations increase and trigger exocytosis of zymogen
granules into the pancreatic ductal system (Lee et al., 2005). These ducts are lined with
columnar epithelial cells (abundant in carbonic anhydrase) that secret large volumes of
water and bicarbonate ions to facilitate the transport of digestive enzymes into the
duodenum (Figure 3) (Petersen, 2018; Nishimori et al., 1999). The alkaline pancreatic
secretions neutralize the gastric acid in the small intestine, providing the neutral pH
pancreatic digestive enzymes require for optimal activity (Nishimori et al., 1999).
Inactive zymogens are converted into active digestive enzymes in the duodenal lumen.
Trypsinogen is converted to trypsin after the cleavage of a peptide fragment by the
enzyme enterokinase, an enzyme produced by duodenal cells. The active trypsin enzyme
then activates chymotrypsinogen (Rinderknecht, 1986).
Pancreatic lipase, or steapsin, is a primary digestive enzyme secreted by the
pancreas (Persson, 1989). The main function of this enzyme is the hydrolysis of fat
molecules consumed in diet. Triacylglycerol (TAG) is broken down into
monoacylglycerol and free fatty acid. Pancreatic lipase, unlike trypsinogen, is secreted in
its active form but requires colipase (co-enzyme) for optimal activity. Serum
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concentrations of this digestive enzyme increase during conditions such as pancreatitis
(Persson, 1989).

Figure 2.2: Electron micrograph image of pancreatic acinar cells showing the
endoplasmic reticulum, Golgi complexes, and zymogen granules involved in the
synthesis and storage of digestive enzymes (Pandol, 2011). Image from
https://www.ncbi.nlm.nih.gov/books/NBK54127.

Figure 2.3: Pancreatic ductal cells secrete an abundant amount of water and bicarbonate
while transporting digestive enzymes to the duodenum (Persson, 1989).
24

Acinar cells have a large number of endoplasmic reticulum (ER), which allow
them to produce and process proteins at a higher frequency than all other human cells
(Palade, 1975). Digestive enzymes are synthesized in the rough endoplasmic reticulum
(RER) (Simon and Blobel, 1993). These newly generated polypeptides undergo
modifications such as glycosylation, phosphorylation, and disulfide bridge formation in
the ER. Polypeptides must also be accurately folded in the ER to be transported to their
correct destination, such as the Golgi complex (GC). Secretion of these stored digestive
enzymes into pancreatic ducts is regulated by concentrations of cytosolic calcium, which
is stored in and released by the ER (Jamieson and Palade, 1971).
Pancreatic acinar cells are especially vulnerable to ER stress, an accumulation of
misfolded proteins in the lumen of ER (Pollard et al., 2017). The processing of large
quantities of proteins along with insufficient ER chaperones, alcohol consumption,
smoking, genetic and environmental factors induce ER stress (Pandol, 2011). Chronic
ER stress can increase cellular reactive oxygen species, induce inflammation, provoke
apoptosis, and result in perpetual cell damage. The unfolded protein response (UPR) is a
mechanism used by cells to relieve ER stress and reestablish normal cell function. UPR
acts to pause protein production, decompose of misfolded proteins, and increase the
synthesis of molecular chaperones for proper protein folding (Chong et al., 2017).
Sustained ER stress from inhibition of the UPR has been implicated in acinar cell damage
leading to acute pancreatitis (Sah et al., 2014), diabetes (Ma et al., 2014), and cancer
(Cubillos-Ruiz et al., 2017).
While secretions from the exocrine pancreas are essential for the digestion of
nutrients, the endocrine pancreas plays an important role in metabolic regulation.
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Endocrine tissue makes up approximately 2% of the pancreas and contains cell clusters
called pancreatic islets (known as islets of Langerhans) (El Sayed and Mukherjee, 2019).
Pancreatic islets are evenly distributed throughout the pancreas with an abundant network
of capillaries, sympathetic, parasympathetic, and sensory nerves (Lacy, 1974). They are
composed of approximately 35% alpha (a), 55% beta (b), less than 10% delta (d), less
than 5% gamma (g), and less than 1% epsilon (e) cells in humans. Pancreatic alpha cells
synthesize glucagon, a hormone that raises blood glucose levels by stimulating the liver
to convert its glycogen into glucose. Beta cells produce and secrete insulin in response to
high concentrations of blood glucose. Delta cells produce somatostatin, a hormone that
suppresses the release of the other hormones made in the pancreas. The gamma cells
produce pancreatic polypeptides, which stimulate the secretion of gastric and intestinal
enzymes. Epsilon cells contain ghrelin, an amino acid peptide shown to inhibit the
secretion of insulin in humans (Lawlor et al., 2017). Endocrine cell heterogeneity
complicates the study of diseases.

2.2 Characteristics of Cancer
Cancer is characterized by distinct genetic mutations that result in the cell’s loss
of control over vital functions (Hanahan and Weinberg, 2011). Cancer cells have
mutated genes with a gain of function or loss of function role. These oncogenes result in
defective regulatory mechanisms that work to maintain homeostasis. As normal cells
evolve into malignant cells, Hanahan and Weinberg proposed that they acquire six
biological capabilities which include: 1) continuing cellular proliferation, 2) escaping
growth suppressors, 3) avoiding cell death, 4) enabling replicative immortality, 5)
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stimulating angiogenesis, and 6) initiating invasion (Hanahan and Weinberg, 2000). This
idea has been supported by studies showing multiple alterations of tumor cell genomes
(Kinzler and Vogelstein, 1996).
The most common trait of cancer cells is continuous cellular proliferation.
Somatic mutations that result in the constant activation of signaling pathways stimulated
by growth factor receptors were revealed by DNA sequencing of tumor tissues. These
mutations have been shown to affect the protein structure B-Raf and alter signaling
through the Raf to mitogen-activated protein kinase pathway (MAPK). In numerous
types of cancer, mutations in phosphoinositide 3-kinase’s (PI3K) catalytic subunit which
triggers protein kinase B (Akt/PKB) signal transduction (Hanahan and Weinberg, 2000).
Additionally, proliferative phenotype is by enriched by mutations of tumor suppressor
genes like PTEN and SMAD4/DPC4. PTEN is a negative regulator of PI3K signaling,
and SMAD4/DPC4 is a tumor suppressor gene for pancreatic cancer (Jiang and Liu,
2009; Fang, 2001). SMAD4 facilitates signal transduction and gene regulation of
members of the transforming growth factor beta (TGF-b) family (Fang, 2001).
The second biological capability mentioned by Hanahan and Weinberg was the
ability to escape growth suppressors, or tumor suppressor genes (Hanahan and Weinberg,
2000). Studies utilizing gain of function/loss of function experiments have identified
dozens of tumor suppressor genes (Hanahan and Weinberg, 2000). One such gene is
TP53, which receives intracellular signals from stress sensors. TP53 can stop cell-cycle
progression in cases of DNA damage, suboptimal growth factor signals, suboptimal
glucose levels, or hypoxia. In instances of devastating damage, apoptosis can be
activated by TP53. A mutation in TP53 that results in its loss of function is frequently
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seen various cancer cells (Levine, 1997). In pancreatic ductal adenocarcinoma (PDAC),
overexpression of mutated TP53 (not loss of expression) was the primary genetic
alteration in individuals with increased serum levels of carbohydrate antigen 19-9 (CA199). Blood serum levels of CA19-9 greater than 1,000 U/mL has been correlated with
inadequate responses to pancreatectomy and low survival rates (Xiang et al., 2016).
More commonly known tumor suppressor genes are APC, BRAC1, and BRAC2.
Research has demonstrated the concept of ‘contact inhibition’ suppressing cellular
proliferation of normal cells making cell-cell contact when grown in cell culture
(Hanahan and Weinberg, 2000). Liver kinase B1 and merlin are tumor suppressor genes
involved in management of contact inhibition. Merlin acts to couple adhesion molecules
on the cell surface, like epithelial cadherin (E-cadherin), to receptors, like epidermal
growth factor receptor (EGFR). This limits the ability of growth factor receptor to
produce mitogenic signals (Curto et al., 2007). Liver kinase B1 assists in preserving
tissue integrity, and a loss of function results in epithelial cell vulnerability to mycinduced transformation (Partanen et al., 2009; Hezel and Bardeesy, 2008). These
systems are important in containing uncontrolled cellular proliferation.
Normal or programmed cell death, apoptosis, eliminates unhealthy somatic cells
without discharging harmful materials into neighboring cells (Elmore, 2007). Influences
such as cell stress, a lack of nutrients, DNA damage, or uninhibited cell growth induce
apoptosis. Resistance to apoptosis in a quality of most cancer cells. Apoptosis is induced
by extracellular signals (extrinsic pathway) or intracellular signals (intrinsic pathway).
The extrinsic pathway entails transmembrane receptor-mediated interactions. Apoptotic
signaling is activated by cell surface receptors binding to their ligands, such as tumor
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necrosis factor (TNF) or FasL (also known as CD95). Somatic mutations of Fas in
cancer cells have resulted in a loss of Fas-mediated apoptosis (Elmore, 2007).
The intrinsic pathway is non-receptor mediated and initiated in the mitochondria
in response to cellular stressor, heat, DNA damage, and radiation (Wang and Youle,
2009). These stimuli change the inner mitochondrial membrane, and pro-apoptotic
proteins are released into the cytosol. One such protein is Cytochrome c, which binds to
apoptosis protease-activating factor 1 (Apaf-1) and complexes with procaspase-9. The
complex activates caspase-9 and commits the cell to apoptosis. However, a decrease in
expression of Apaf-1has been seen in melanoma. Cancer cells also escape cell death
through the loss of TP53 function. This results in the loss of apoptosis-inducing damage
sensors (Wang and Youle, 2009).
Enabling replicative immortality involves telomerase activity. Numerous studies
have indicated that telomeres protecting the ends of chromosomes allow unlimited
proliferation (Jafri et al., 2016). In nonmalignant cells, telomeres shorten and lose their
capability to protect the ends of chromosomal DNA as cells divide. The consequences of
the eventual loss of telomeres is chromosomal end to end fusion and cell crisis.
Telomerase, an enzyme that aids in the maintenance of telomere length, is not found in
nonmalignant cells but overexpressed in human cancer cells. Cancer cells that obtain the
benefit of telomerase activity acquires replicative immortality (Shay and Wright, 2000).
The vascular system provides cells with a means of gas and metabolic exchange.
During embryogenesis, new endothelial cells form the vasculature system. This system
stops developing in adulthood, but it can be ‘turned on’ during certain physiological
conditions such as wound healing. In cancer cells, angiogenesis is activated and remains
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on to sustain cell growth. Analyses of premalignant lesions have revealed the angiogenic
switch to be on at this early stage. Variation in tumor microenvironments will result in
different angiogenic signals (Hanahan and Folkman, 1996).
Tumors formed from epithelial tissues develop modifications in their attachment
to other cells and to the extracellular matrix (ECM) (Frantz et al., 2010). A reduction in
epithelial cadherin (E-cadherin) expression, an adhesion molecule, has been associated
with cell migration. Transformed epithelial cells have primarily attained invasion ability
through a process called epithelial-mesenchymal transition (EMT) (Yilmaz and
Christofori, 2009; Klymkowsky and Savagner, 2009). EMT is a biological process that
changes polarized epithelial cells into a mesenchymal phenotype. Some of the cells
undergoing this process will present with differentiated characteristics while others have
characteristics of stem cells. This contributes to heterogeneity within tumor tissues
(Polyak and Weinberg, 2009). Various factors in the tumor microenvironment such as
hypoxia, tumor necrosis factor alpha (TNFa), and cytokines are able to induce EMT
(Maier et al., 2010). These cells exhibit reduced expression levels of E-cadherin,
occludin, and claudin. However, there is an increase in expression of N-cadherin,
vimentin, and fibronectin. Transcription factors inducing EMT are able to organize
invasion and metastasis (Barriere et al., 2015).

2.3 Pancreatic Cancer
Tumors that originate in the endocrine pancreas are neuroendocrine tumors (NET)
and occur in approximately 2.2 per 1,000,000 individuals. A relative five-year survival
rate of 30% for non-functioning PNETs and 97% for functioning PNETs has been
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reported by the National Cancer Institute (NCI) (Ro et al., 2013). A majority of these
tumors are non-functioning, and they are not associated with excessive secretion of
hormones. Functioning PNETs are associated with increased levels of hormones and
produce hormone-related syndromes, such as insulinomas. Individuals with insulinoma
experience hypoglycemic symptoms with high blood glucose levels (Ro et al., 2013).
The prognosis of endocrine tumors is generally higher than exocrine tumors.
PDAC, cancer originating in the pancreatic ducts, has a high mortality rate and
often detrimental to most individuals. The ACS reports a relative five-year survival rate
of 34% with early stage diagnoses, and this rate drops to 3% with metastasis (Noone et
al., 2017). It is estimated that approximately 45,750 people will perish due to PDAC in
2019, and this disease will occur more frequently in men than women (Noone et al.,
2017). Chronic pancreatitis (Etemad and Whitcomb, 2011), diabetes mellitus (Sharma
and Chari, 2018), alcohol and tobacco use (Zhang et al., 2017), and genetics (Cowan and
Maitra, 2014) have been identified as risk factors. An increased risk of developing
PDAC has been linked to mutations in multiple genes including KRAS, BRAC2,
p16/CDKN2A, PRSS1, and SK11. However, the poor prognosis and low survival rate of
individuals suffering from this disease can be attributed to a lack of information
underlying its molecular processes and complex biology. This complexity is due to
intrinsic factors, such as genetic and epigenetic heterogeneity within a tumor, and
extrinsic factors, such as tumor microenvironment. These factors result in large
variations in the degree to which cancer cells invade and metastasize (Gupta and
Massagué, 2006).
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PDAC consists of pancreatic epithelial tissue that transitioned to a precursor
lesion (Distler et al., 2014). There are three distinct noninvasive precursor lesions of
PDAC. Among these precursors are intraductal papillary neoplasms (IPNs), mucinous
cystic neoplasms (MCNs), and pancreatic intraepithelial neoplasia (PanINs). While
MCNs are mucin-producing cyst-forming neoplasms, IPMNs are mucin-like epithelial
tumors. PanINs are the most common. They are classified according to their ductal
epithelial tissue of origin and degree of abnormality. PanINs are small epithelial tumors
found in small pancreatic ductal tissue. Genes in advance PanIN lesions become
unpredictable, proliferate, and establish a dense stromal microenvironment. The stromal
tissue becomes more developed as the precancerous lesion progresses (Distler et al.,
2014).
Genetic mutations in genes the KRAS (90%), CDKN2A/p16 (90%), TP53 (70%),
and mothers against decapentaplegic homolog 4 (SMAD4) (55%) genes occur throughout
the development of PDAC (Lu et al., 2017). Transcription of the mutant KRAS gene is
present in 90% of all cases of PDAC, and the most prevalent instigating factor in
precursor lesions. KRAS mutations frequently occur at codons 12, 61, and 13. KRAS is
involved in multiple important cellular functions including cell survival, cell
differentiation and cellular proliferation. KRAS triggers Ras and activates uncontrolled
proliferation, or inactivation of CDKN2A (Waters and Der, 2018). With this
inactivation, there is a loss of p16 protein (cell cycle’s G-1 to S regulation) resulting in
uncontrolled cellular proliferation (Li et al., 2011). Cells escape apoptosis with
inactivation of TP53, and SMAD4 occurs frequently in later stages of development. In
many forms of cancer, an accumulation and coexistence of genetic mutations. In PDAC,
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hypoxia inducible factor-1 works with oncogenic KRAS and loss of p53 to increase
upregulation of glucose transporters (Prunier et al., 2011).
Currently, there are no precise diagnostic exam or testable biomarker for PDAC.
Carbohydrate antigen 19-9 (CA 19-9) is the only tumor marker available for pancreatic
cancer. It has been successful in 75-85% of individuals positive for PDAC (Poruk et al.,
2013). Since a highly successful laboratory test for PDAC is not available, the primary
diagnostic approach is imaging. An abdominal computed tomography (CT) scan is the
most common test performed to look for a mass, which is a signature of the tumor.
However, other available methods include magnetic resonance imaging (MRI) with or
without cholangiopancreatography (MRCP) and ultrasonography (Lee and Lee, 2014).
Previous research suggests PanIN lesions progress to PDAC tumors by
undergoing a lengthy process (Valkenburg et al., 2018). First, an oncogenic mutation
transforms pancreatic cells. Next, clonal and tissue expansion occurs when the mutant
cells are the dominant phenotype. Finally, a loss of function (tumor suppression) makes
invasion possible (Ying et al., 2016). A dense desmoplastic reaction surrounds the
malignant cells. This stroma is made up off various types of cells (endothelial, immune,
pericytes), fibroblasts, and extracellular proteins. TGFb and EGF increase stromal
fibrosis as a response to wound healing. This strengthens the stroma allowing it to act
like a tumor shield. This results in a hypoxic microenvironment, drug resistant PDAC,
and immune suppression (Valkenburg et al., 2018).
A hypoxic tumor microenvironment is typical for many malignant tumors (Muz et
al., 2015). In order to maintain adequate nutrient levels, PDAC enables metabolic
reprogramming. Hypoxia inducible factor-1 (HIF-1) is the transcription factor induced
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under hypoxic conditions. It works with oncogenic KRAS and loss of p53 to increase
upregulation of glucose transporters. In addition, increased levels of lactate are secreted
by the hypoxic cells to acidify the microenvironment. Lactate can be used by more
oxygenated cells in the area, encouraging a symbiotic relationship (Abhishek et al.,
2018).
PDAC tumors overexpress epidermal growth factor receptor ligands (EGFR), like
transforming growth factor-alpha (TGF-α). Autocrine EGF signaling is present in PaINs
and growth inhibition was seen in PDAC cells after blocking EGFR with antibodies, so
this signaling pathway is known to play a part in tumorigenesis (Narayanan and Weekes,
2016). EGF signaling is the result of phosphatidylinositol-3-kinase (P13K) pathway.
P13K induces Akt and mTOR signaling and activates metabolic pathways enhancing
macromolecular biosynthesis. This increases expression of nutrient transports and
glycolysis with Akt stimulating the production of lipids (Fruman et al., 2017).

2.4 Cancer Cell Metabolism
Metabolism and metabolic adaptation were the first areas studied in cancer cells
(DeBerardinis and Chandel, 2016). Many metabolic pathways are altered in cancer cells,
in comparison to normal cells, for them to support proliferation, evade apoptosis, and
stimulate metastasis. Glycolysis, the stepwise breakdown of glucose from carbohydrates
to produce pyruvate with the production of adenosine triphosphate (ATP), is a means
cells can harness ATP for energy. An additional enzymatic reaction occurs in the
absence of molecular oxygen (hypoxia) which converts pyruvate to lactate. Research has
shown that cancer cells preferentially metabolize glucose by glycolysis to lactate, even
with sufficient oxygen to support mitochondrial function (Kim and Dang, 2006; Dong et
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al., 2017). This is known as aerobic glycolysis or the ‘Warburg Effect’. This metabolic
switch provides an organized effect with varying components to cancer cells (Dong et al.,
2017).
Mitochondrial ATP production is maintained by fatty acids and amino acids that
provide substrates to the tricarboxylic acid (TCA), or Krebs, cycle in cancer cells.
Acetyl-CoA (coenzyme A) is generated by the breakdown of fatty acids by betaoxidation in the mitochondria. When acetyl-CoA is oxidized, high energy electrons are
released forming reduced nicotinamide adenine dinucleotide (NADH) and reduced
adenine flavin dinucleotide (FADH2). In the electron transport chain (ETC), electrons
from these high energy molecules are transferred to low energy molecules such as O2.
This results in the formation of mitochondrial ATP. Nutrient and O2 availability to cells
within a solid tumor is dependent on each cell’s proximity to blood vessels. While cells
located near blood vessels can nourish anabolic pathways, cells distant from blood
vessels may use another form of metabolism due to limited access to nutrients and O2.
Cancer cells often turn to alternate forms of metabolism such as oxidation of fatty acids
and use of amino acids, as well as autophagy (Figure 2.4). Additionally, branched-chain
amino acids that are often higher in blood plasma of pancreatic cancer patients
(isoleucine, valine, and leucine) can be converted into acetyl-CoA. Various contributions
into the TCA cycle allows cancer cells to utilize the nutrients that are accessible in their
microenvironment (DeBerardinis and Chandel, 2016).

35

Figure 2.4: Metabolic pathway under nutrient-deprived conditions (DeBerardinis and
Chandel, 2016). Image from Science at
https://advances.sciencemag.org/content/2/5/e1600200.
2.5 Angiopoietin-like 4 (ANGPTL4)
Angiopoietin proteins (1-4) are modulators of angiogenesis and maintain the
integrity of the vascular system. Members of this protein family bind to receptor tyrosine
kinase (Tie2) expressed on endothelial and hematopoietic cells. Angiopoietins are
proteolytically cleaved into an amino-terminal coiled-coil domain (nANG) and a
carboxyl-terminal fibrinogen-like domain (cANG). The amino-terminal domain
promotes the formation of higher-order multimers while the carboxyl-terminal domain
contains the binding site for Tie2. Angiopoietin1-Tie2 signaling is essential in the
regulation of angiogenesis and vascularization (Hato et al., 2008; Zhu et al., 2012).
Angiopoietin-like protein 4 (ANGPTL4) is one of eight members in a family of
angiopoietin-like proteins (ANGPTL1-8). ANGPTL4 was detected during a probe for
targets of peroxisome proliferator-activated receptor alpha (PPAR-a). ANGPTLs have a
similar structure as angiopoietins and play a role in angiogenesis, but do not bind to Tie2.
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The human ANGPTL4 gene is located on chromosome 19p13.3, and the gene encodes a
45–65 kDa protein. Inconsistencies in reported molecular masses are due to tissue related
isoforms and glycosylation (Yang et al., 2008).
This full-length protein is cleaved into an amino-terminal coiled-coil domain
(nANGPTL4), and a carboxy-terminal fibrinogen-like domain (cANGPTL4) when proprotein convertases recognize the major cleavage site between Lys168 and Lev169.
A minor cleavage site is located between Lys170 and Met171. However, the
cleavage of ANGPTL4 is contingent upon the expressing tissue. fANGPTL4 and the
individual domains have been found in blood plasma (Lei et al., 2011).
Human ANGPTL4 is expressed at notable levels in adipose, heart, muscle, liver,
lung, and endothelial cells (Tjeerdema et al., 2014). Adipose tissue is believed to express
copious amounts (Yoon et al., 2000; Kim et al., 2000). Studies have shown that
expression levels of ANGPTL4 are managed by peroxisome proliferator-activated
receptors (PPAR), transcription factors of nuclear hormone receptors (Inouse et al.,
2014). Biological conditions such as fasting, chronic caloric restriction, fatty acid
signaling, hypoxia, and hypoxia inducible factor-1a (HIF-1a) can induce the expression
of ANGPTL4 (Kim et al., 2011). While glucocorticoids stimulate expression in liver and
adipose tissue, insulin suppresses it in adipose tissue (Kuo et al., 2014). Adipocytes
express the post-translationally modified flANGPTL4 (65 kDa), whereas liver tissue will
express both cANGPTL4 (47 kDa) and nANGPTL4 (26 kD) (Yang et al., 2008; Lei et
al., 2011).
ANGPTLs 3, 4, and 5 seem to be involved in maintaining processes such as lipid
metabolism, glucose metabolism, and energy homeostasis. ANGPTL4 inhibits the
activity of lipoprotein lipase (LPL), which breaks down circulating triglyceride into fatty
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acids and glycerol to be taken into cells. LPL is expressed and secreted by adipocytes
and muscle cells. Once ANGPTL4 is cleaved, two conserved cysteine residues (Cys76
and Cys80) of nANGPTL4 form a disulfide bond mediating oligomerization. This is
essential for nANGPTL4 binding to lipoprotein lipase (LPL), converting the catalytically
active dimer into an inactive monomer (Sukonian et al., 2006; Lichtenstein et al., 2007).
In order to maintain cellular activities, the production of free fatty acids for betaoxidation is stimulated during fasting. Free fatty acids induce expression of ANGPTL4,
and there is a decrease in LPL activity (Lichtenstein et al., 2007).
Simultaneously, ANGPTL4 plays a role in intracellular lipolysis. Studies have
shown a blunt increase of free fatty acids in blood plasma when the ANGPTL4 has been
silenced (Aryal et al., 2018). Additionally, findings have indicated that ANGPTL4 plays
a key role in fat metabolism. Mice overexpressing ANGPTL4 protein in white adipose
tissue harbored elevated levels of triglycerides and free fatty acids (Kersten et al., 2009).
ANGPTL4 has been implicated in glucose metabolism. In adipocytes, insulin has
been shown to down regulate ANGPTL4 levels through the PI3K/FOXO1 signaling (Kuo
et al., 2014). In another study, feeding subjects after a period of starvation resulted in
elevated insulin levels with decreased levels of ANGPTL4 (Xu et al., 2005). Finally,
overexpression of ANGPTL4 was correlated with improved glucose tolerance (Xu et al.,
2005).
Angiopoietin-like 4 (ANGPTL4) was shown to be overexpressed in human
pancreatic cancer cells that are resistant to gemcitabine chemotherapy (Kirbya et al.,
2016), expressed in human colorectal cancer (Nakayama et al., 2011), to mediate the
endothelial migration of breast cancer cells resulting in lung metastasis (Padua et al.,
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2008) , and plays a key role in Kaposi’s sarcoma (Hu et al., 2011). Expression levels
were found to be associated with survival time from diagnosis in individuals suffering
from gemcitabine resistant pancreatic cancer. Individuals with higher expression levels
fell into the “short survival” category. Results revealed that elevated ANGPTL4
expression is present in all epithelial tumor samples, and its expression is correlated with
the tumor progression (Kirbya et al., 2016).
The role of ANGPTL4 in cancer progression remains poorly understood.
Research has focused on elucidating the role of ANGPTL4 in angiogenesis. ANGPTL4
has been found within several perinecrotic tumors under hypoxic conditions (Kim et al.,
2011). Studies have shown evidence of ANGPTL4 involvement in other roles during
cancer progression. ANGPTL4 was indicated in enabling cancer cell survival
maintaining elevated levels of oxygen radicals (Zhu et al., 2011). Further research
revealed cANGPTL4 interacts with integrin α5β1, VE-cadherin and claudin-5 to disrupt
endothelial stability through integrin-mediated PAK/Rac signaling (Huang et al., 2011).
Additional studies that determine the interacting residues of cANGPTL4 to each binding
partner would provide better insight and determine the role of cANGPTL4 in cancer
progression. Studies that include X-ray crystallography, Cryo-EM, ITC data, and sitedirected mutagenesis would examine these key interactions providing an increased
mechanistic understanding. Furthermore, investigations into the interactions of
cANGPTL4 with both cell surface and intracellular proteins, as well as interactions with
potential physiological ligands, are needed to provide better insight into the full scope of
the role of ANGPTL4 in cancer progression.
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Proteomics is the broad study of proteins in biological samples and some
examinations include their structure-function, abundance, post-translational
modifications, and interactions (Chandramouli and Qian, 2009). Protein-protein and
protein-ligand binding are essential for many biological functions. Therefore, protein
research is heavily focused on protein binding sites and their properties. For example,
many binding sites are prone to be more hydrophobic. Some binding sites demonstrate
structural flexibility by binding to multiple proteins or ligands and contain highly
conserved residues (Patil et al., 2010). Structural studies involving cANGPTL4, several
carbohydrates, and various fatty acids will be performed in this project to investigate
possible binding sites of ANGPTL4.
Angiopoietin-like 4 (ANGPTL4) is indicated in the progression of several types
of aggressive cancer. Biochemical studies have been performed but a full structural
understanding of functions and interactions is not available. The goal of this project is to
gain insight into structural interactions that result in the progression of PDAC in order to
enable therapeutic development. Overexpression of cANGPTL4 has been found in
pancreatic tumor tissues of all stages. Its complexity and ability to target various cancer
cell microenvironments, endothelial cells, and metabolic activities makes it a prime
candidate for therapeutic intervention. The primary function of a protein depends on its
structure, and changes in protein conformations or binding to other proteins can lead to
altered protein functions. We provide significant insight into the actions of cANGPTL4
through structure-function studies. This research is significant in that previously
unknown properties of cANGPTL4 is shown for the first time. The crystallographic
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derived structures elucidated in this work were deposited on the protein data bank to
enable future structural studies.

41

Chapter 3

Differential Expression and Secretion of Hypoxia-Induced
ANGPTL4 in Cancer Cell Lines

3.1 Introduction
The relative five-year survival rate for individuals with pancreatic ductal
adenocarcinoma (PDAC) drops to 3% with metastasis (Noone et al., 2017). PDAC is
responsible for approximately 6% of cancer related deaths annually. Due to vague
symptoms and late stage diagnosis, only 10-20% of newly diagnosed patients will have
operable tumors (Noone et al., 2017). Historically, chemotherapy with gemcitabine has
been the standard treatment, but PDAC tumors have an intrinsically high resistance to
chemotherapeutics (Amrutkar and Ivar, 2017). A complete system approach using
genomics to look for mutations, epigenomics for chemical modifications, transcriptomics
for quantification of RNA transcripts, proteomics for analyses of proteins, and
metabolomics to quantify metabolites has the potential to overcome chemoimmunotherapy resistance in PDAC.
Angiopoietin-like 4 (ANGPTL4), a secreted signaling protein, has been linked to
the progression of several types of aggressive cancer. This protein has been shown to
mediate the endothelial migration of breast cancer cells resulting in lung metastasis
(Padua et al., 2008), over-express in human colorectal cancer (Nakayama et al., 2011),
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and play a key role in Kaposi’s sarcoma (Hu et al., 2011). In a previous study,
differentially expressing gene transcripts were detected from pancreatic tumor tissues of
individuals with different life expectancies. ANGPTL4 was identified as a transcript
with greater expression in individuals with a shorter life expectancy and pancreatic
cancer cells resistant to gemcitabine (Kirbya et al., 2016). However, the role of
ANGPTL4 in cancer progression remains poorly understood.
Human ANGPTL4 is one of eight members in a family of angiopoietin-like
proteins (ANGPTL1-8) (Yang et al., 2008). Native full-length ANGPTL4 (fANGPTL4)
is cleaved into an amino-terminal coiled-coil domain (nANGPTL4), and a carboxyterminal fibrinogen-like domain (cANGPTL4) by proprotein convertases. The
cleavage site is contingent upon the expressing tissue. Adipocytes secrete the posttranslationally modified flANGPTL4 (65 kDa), whereas liver tissue secrets nANGPTL4
(26 kDa) (Lei et al., 2011). After cleavage, nANGPTL4 regulates lipid metabolism by
inhibiting activity of lipoprotein lipase (LPL), which breaks down circulating triglyceride
into fatty acids and glycerol to be taken into cells (Lichtenstein et al., 2007). Numerous
studies have indicated cANGPTL4 plays multiple molecular roles in cancer cell
progression, but its mechanisms of action are poorly understood.
Differential expression of proteins has been correlated to phenotypic
characteristics such as invasion, migration, tumorigenesis, and chemotherapeutic drug
resistance (Tan et al., 2012). Cell culture experiments are widely used to study normal
biological processes (like metabolism), cellular effects of various chemicals,
mutagenesis, and oncogenesis. Cancer cell lines were selected based on phenotypic
characteristics such as anoikis resistance, invasion, proliferation rate, metastasis, and
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tumorigenesis for this study. Additionally, the four most frequently altered genes in
pancreatic tumors (KRAS, p53, p16, and SMAD4) were also considered (Deer et al.,
2010). These mutations are found at similar percentages in the pancreatic cancer cell
lines used in this project. The pancreatic cancer cell lines used in this study were Capan1, MiaPaCa2, and Panc-1 cells. Capan-1 cells were derived from an adenocarcinoma
found in the head of the pancreas (Deer et al., 2010). Cells had metastasized to the
lymph nodes. MiaPaCa2 cell were found in an adenocarcinoma located in the body and
tail of a pancreas, and cells had invaded the periaortic region (Deer et al., 2010). Panc-1
cells originally removed from an adenocarcinoma located in the head of the pancreas
with invasion into the duodenal wall and metastasis into a peripancreatic lymph node
(Deer et al., 2010). Proliferation rate differences have been reported depending on
culture conditions (Deer 2010).
Relative phenotypic differences in behaviors such as adhesion, migration,
tumorigenicity, and invasion have been previously evaluated for each cell line used in
this study (Deer et al., 2010). Panc-1 cells have shown the greatest mobility. They
exhibited a five-fold greater mobility than BxPC-3 cells. Invasive properties of cells used
in this study were previously determined and rank from most to least invasive as follows:
MiaPaCa2>Capan-1>Panc-1. Angiogenic potential is assessed by expression levels of
pro-angiogenic cytokines and enzymes, such as cyclooxygenase-2 (COX2). Capan-1
cells have steadily presented high levels of pro-angiogenic factors while MiaPaCa-2 cells
have shown consistently low levels. A cancer cell’s propensity to generate a tumor is
called tumorigenicity. Capan-1 tumorigenicity is greater than MiaPaCa2 cells, while
MiaPaCa2 cells have higher tumorigenicity than Panc-1 cells (Deer 2010).
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The microenvironment of solid tumors is known to have low oxygen levels,
hypoxic, compared to normal tissues of the same organ (Vaupel et al., 1989). Blood
vessels in tumor tissue can elongate, disintegrate, or become compressed. This reduces
the exchange area for oxygen and other products. When this occurs, normal cells die, and
cancer cells adapt to the hypoxic environment through metabolic reprogramming. An
example of this can be seen in PDAC. A median pO2 of 24.3-92.7 mmHg (3.2-12.3%)
has been reported for normal pancreatic tissue, with pancreatic tumor tissue at pO2 0-5.3
mmHg (0-0.7%) (Vaupel et al., 1989). Normal arterial blood pO2 is 100 mmHg (13.2%),
and typical room air pO2 is 160 mmHg (21.1%) (Vaupel et al., 1989). Hypoxia induces
multiple intracellular signaling pathways, such as hypoxia inducing factor (HIF),
involved in apoptosis, proliferation, metabolism, and metastasis (Vaupel et al., 1989). In
this study, pancreatic cancer cells were cultured in both normoxic and hypoxic conditions
to mimic tumor cell microenvironment.
The aim of this study was to examine the molecular role of ANGPTL4 in PDAC
progression. A relationship was shown between expression levels of ANGPTL4 and
phenotypic characteristics of pancreatic cancer cells. In this chapter, the various
ANGPTL4 isoforms were detected and identified to help reveal a structure-function
relationship. Additionally, cellular location of cANGPTL4 and integrin-b1 was in
examined by immunofluorescence and confocal imaging.

3.2 Material and Methods
Antibodies and reagents used included mouse monoclonal anti-human
fANGPTL4 (26-406) antibody (LSBio), rabbit polyclonal anti-human cANGPTL4 (184-
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336) antibody (Abcam), rabbit polyclonal anti-human nANGPTL4 (26-166) antibody
(Abcam), integrin b1 antibody (Abcam), E-cadherin antibody (Cell Signaling
Technologies), HIF1a (Santa Cruz Biotechnology); Alexa Fluor 488-conjugated
secondary antibodies (Molecular Probes), Alexa Fluor 594-conjugated secondary
antibodies (Molecular Probes), Alexa Fluor 647-conjugated secondary antibodies
(Molecular Probes), Alexa Fluor 680-conjugated secondary antibodies (Molecular
Probes); Actin-red 555 (Molecular Probes), and Nuc-blue (Molecular Probes); 5hexadecanoyl fluorescein (Molecular Probes) and 4,4-difluoro-5,7-dimethyl-4-bora3a,4a-diaza-s-indacene-3-hexadecanoic acid (BODIPY-FL C16) (Molecular Probes).
Pancreatic cancer cell lines were purchased from Sigma-Aldrich, and breast cancer cell
lines were a generous gift from Dr. Debra Moriarity.

3.2.1 Cell lines and cell culture
Human pancreatic cell lines Panc-1, MiaPaCa2, Capan-1, HEK293, and SKBR3
cells were cultured in complete Dulbecco’s Modified Eagle’s Medium (DMEM/SigmaAldrich) supplemented with 10% fetal bovine serum (Sigma-Aldrich) and 100 U/ml
penicillin with 0.1 mg/ml streptomycin (Gibco). Human breast cancer cell lines MCF7
and MDA-MB231 were cultured in RPMI 1640 (Sigma-Aldrich) medium supplemented
with 10% fetal bovine serum (Sigma-Aldrich) and 100 U/ml penicillin with 0.1 mg/ml
streptomycin (Gibco). MCF7 cell medium was supplemented with 0.01mg/mL insulin.
All cell lines were grown in 75 cm2 sterile flasks at 37°C in a humidified atmosphere at
5% CO2 and 20% O2 (normoxia). For hypoxia, cell culture medium was replaced with
serum-free medium and grown in a humidified atmosphere at 1% O2, 5% CO2, and 94%
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N2. All cell lines were periodically tested to be mycoplasma free using an assay kit by
Lonza (MycoAlert Mycoplasma Detection Kit #LT07-418) using the protocols provided
with the kit.

3.2.2 Protein secretion analysis
Cells (~2 X 107) were cultured in serum-free medium in a 25 cm2 sterile flasks at
37°C. The serum-free conditioned medium was collected from each flask of cells after
incubation in normoxia or hypoxia for 48 hours. Each flask of conditioned medium was
filtered through a 0.22 µm filter for debris removal. A 10 kDa spin column was used to
concentrate the conditioned medium. Protein concentrations were quantified (50 ng/µL),
and approximately 5 µL of each were added to three different gradient SDS gels for
immunoblots, and two SDS gels for analysis using Coomassie blue. Proteins from three
gels were transferred to nitrocellulose membranes, while two SDS-PAGE underwent
staining with Coomassie blue and de-staining. The membranes were blocked in 5% BSA
overnight at 4°C. The membranes were washed 3 times for 10 minutes in 1X TBST
solution. One membrane was incubated in primary antibody for fANGPTL4 (diluted
1:1000 in blocking solution + 0.1% Tween-20); the second membrane was incubated in
primary antibody for nANGPTL4 (diluted 1:1000 in blocking solution + 0.1% Tween-20)
and then in primary antibody for cANGPTL4 (diluted 1:1000 in blocking solution + 0.1%
Tween-20) overnight at 4°C. The third membrane was incubated overnight at 4°C in
primary antibody for b-actin for a positive control. Each membrane was washed 3 times
for 10 minutes in 1X TBST and incubated with HRP-conjugated anti-species secondary
for one hour. Then, each membrane was developed using an enhanced
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chemiluminescence kit (Pierce 32106). These membranes were also stripped and reprobed for HIF1a to confirm hypoxia. Protein bands for HIF1a were seen on
immunoblots but results are not shown due to problems with imaging.

3.2.3 RNA extraction and real-time quantitative polymerase chain reaction (RTqPCR)
RNA was extracted with TRIzol according to manufacturer’s instructions
(Invitrogen). cDNA reverse transcription was performed for cANGPTL4 using a High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Concentrations of
cDNA samples were determined by nanodrop, and equal amounts were used for real time
qPCR (ABI Prism). Primer sequences for genes of interest are as follows: ANGPTL4
(sense, 5’- TCCAACGCCACCCACTTAC-3’; antisense,
5’-TGAAGTCATCTCACAGTTGACCA-3’), b-actin (sense,
5’- ACGCCTCTGGCCGTACCACT-3’; antisense,
5’- TAATGTCACGCACGATTTCCC -3’), and 18S rRNA (sense,
5’- CTACCACATCCAAGGAAGCA-3’; antisense,
5’-TTTTTCGTCACTACCTCCCCG-3’. All samples were run in triplicate and
normalized to b-actin.

3.2.4 Cell proliferation assay
Cells (1 X 105) from each cell line listed above were grown in appropriate growth
medium in 24-well plates in normoxia and hypoxia for 24, 48, and 72 hours. One plate of
each cell line was collected, trypsinized, and counted using trypan blue stain (Sigma) at
each time interval in triplicate.
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3.2.5 Immunofluorescent Confocal Imaging
Cells (~3 X 105) from each cell line listed above were grown in appropriate
growth medium to approximately 85% confluency on hydrophilic, tissue culture treated
Ibidi microchamber plates in normoxia and hypoxia. Growth medium were removed, and
cells were washed with PBS prior to fixation with 4% paraformaldehyde for 10 minutes.
Cells were washed three times in PBS, briefly washed with 0.1M ammonium chloride,
washed again with PBS, and blocked with 3% normal goat serum) for 1 hour at room
temperature. Following three washes in PBS, cells were incubated overnight at 4 °C with
either anti-human fANGPTL4, nANGPTL4, cANGPTL4, Integrin b1, E-Cadherin, or
HIF1a antibody. After three washes with PBS at room temperature, cells were incubated
with Alexa Fluor 488, Alexa Fluor 594, Alexa Fluor 647, or Alexa Fluor 680 secondary
antibodies for 2 hours. Actin-red 555 and Nuc-blue were added for actin and nuclear
staining. Imaging was performed with staining but without presence of a primary
antibody, as well as without staining but with a primary antibody as controls. Images
were acquired using a Zeiss LSM710 confocal microscope.

3.2.6 Statistical analysis

Statistical analyses were performed in triplicate with two-tailed Mann-Whitney
test and graphs created with GraphPad Prism (GraphPad Software). A statistically
significant difference was considered p < 0.05.
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3.3 Results
3.3.1 Protein secretion analysis
To identify the secretion of ANGPTL4 protein isoforms, pancreatic and breast
cancer cell lines were cultured in normoxia and hypoxia. No protein bands were detected
with immunoblot analysis of serum-free conditioned medium from cells grown under
normoxia for 48 hours. However, secretion of ANGPTL4 protein was elevated under
hypoxia in each cell line. Samples of concentrated serum-free conditioned medium from
cell lines cultured under hypoxia for 48 hours were analyzed by SDS-PAGE stained with
Coomassie blue and immunoblots. A protein band was seen at the expected molecular
weight for fANGPTL4 from Panc-1, Capan-1, MDA-MB231, MCF7, and SKBR3
conditioned medium, but not MiaPaCa2 on the SDS-PAGE and confirmed on the
immunoblot (Figure 3.1). A sample of recombinant fANGPTL4 was added to the gel and
immunoblot as a control. Also, a protein band was also seen at the expected molecular
weight for nANGPTL4 from MiaPaCa2 and Capan-1 conditioned medium on the same
SDS-PAGE. Proteins from another SDS gel were transferred to a nitrocellulose
membrane that was probed for both cANGPLT4 and nANGPTL4, but not fANGPTL4.
Primary antibodies specifically for cANGPTL4 and nANGPTL4 were used with this
immunoblot to prevent any possible interference from fANGPTL4. The internal marker
b-actin was a positive control. This immunoblot was ran with samples from the same
serum-free conditioned medium, but on a separate SDS gel and nitrocellulose membrane
in order to avoid stripping and re-probing the membrane.
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B

Figure 3.1: Immunoblot and SDS-PAGE analysis of ANGPTL4 protein secretion from
pancreatic and breast cancer cell lines under hypoxia for 48 hours. A) In the top panel, a
protein band was seen for fANGPTL4 from Panc-1, Capan-1, MDA-MB231, MCF7, and
SKBR3 serum-free conditioned medium, but not MiaPaCa2. A sample of recombinant
fANGPTL4 was added as a control. In the middle panel, a protein band for nANGPTL4
was seen only from MiaPaCa2 and Capan-1 conditioned medium. The cANGPTL4
isoform was not seen from any of the cell lines, and the internal marker b-actin is shown
in the bottom panel. B) SDS-PAGE stained with Coomassie blue showing protein bands
at expected molecular weights for fANGPTL4 and nANGPTL4. Each sample was
obtained from serum-free conditioned medium from cells grown in hypoxia for 48 hours.
Lane 1 contains a molecular weight ladder. The remaining lanes are organized as
samples from cells as follows: Panc-1, MiaPaCa2, Capan-1, MDA-MB231, MCF7,
SKBR3. The last lane contains fANGPTL4 control.
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3.3.2 ANGPTL4 expression under normoxia and hypoxia
In order to study differential expression of ANGPTL4 in various cancer cell
phenotypes, various pancreatic and breast cancer cell lines were grown in normoxia and
hypoxia for 48 hours prior to RNA extraction. Both cancer cell lines under normoxia for
48 hours expressed minimal RNA as revealed by RT-qPCR (Figure 3.2). Under hypoxia,
ANGPTL4 RNA expression was significantly elevated in all cancer cell lines but not in
HEK293 cells. The most significant increase was seen in Panc-1 and MDA-MB231 cell
lines. Capan-1 cells exhibited the third largest increase in expression under hypoxia.
Overall, these results show ANGPTL4 expression levels are significantly increased in
cancer cells under hypoxic conditions as found within a tumor microenvironment
(Vaupel 1989).

Figure 3.2: Analysis of ANGPTL4 expression by RT-qPCR in pancreatic and breast
cancer cell lines cultured under normoxia and hypoxia for 48 hours. Relative expression
was determined as the expression ratio of ANGPTL4 RNA/b-actin RNA. Data were
collected in triplicate and presented as mean±SD. ANGPTL4 expression was
significantly increased in all cell lines grown in hypoxia in comparison to cells grown in
normoxia, except HEK293 cells. The most significant increase was seen in Panc-1 and
MDA-MB231 cell lines. Capan-1 cells exhibited the third largest increase in expression
under hypoxia. p values <0.05 indicate a significant difference.
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3.3.3 Cell proliferation assay
To investigate the effects of increased ANGPTL4 expression on cellular
proliferation, Panc-1, MiaPaCa2, and Capan-1 cells were grown in normoxia and
hypoxia. Cells from each line were collected and counted after 24, 48, and 72 hours in
triplicate. While expression levels of ANGPTL4 did significantly increase, cellular
proliferation rates did not increase for any of the cell lines (Figure 3.3). In fact,
proliferation of each cell line was greater under normoxic conditions. However, fewer
dead cells were noted in cultures grown in hypoxia.

Figure 3.3: Cellular proliferation of (A) Panc-1, (B) MiaPaCa2, and (C) Capan-1 cells
grown in normoxia and hypoxia. Cells from each line were collected and counted after
24, 48, and 72 hours from initial seeding. While expression levels of ANGPTL4 did
significantly increase in each cell line, cellular proliferation rates did not increase for any
of the cells in hypoxia.
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3.3.4 Cellular localization of ANGPTL4 isoforms
Immunofluorescent labeling and confocal imaging were used to examine cellular
localization of fANGPTL4, nANGPTL4, and cANGPTL4. This protein plays multiple
molecular roles in cancer cell progression, but its mechanisms of action are poorly
understood. Three cleavage isoforms of this protein with independent and multiple
cellular functions complicates things (Tan et al., 2012). The expression levels were
elevated under hypoxia, as shown by RNA analysis. However, only fANGPTL4 and
nANGPTL4 protein isoforms were found in conditioned medium. Since cleavage of
fANGPT4 produces both n- and cANGPTL4, it was hypothesized that cANGPT4 bound
to the cell surface.
Confocal images show that none of this protein’s isoforms were detected in
pancreatic or breast cancer cell lines cultured in normoxia. In hypoxia, cANGPTL4
(green fluorescence) was identified on the extracellular surface of Panc-1 and MDAMB231 cells (Figure 3.4). This fluorescent signal was also seen with less intensity in the
other cancer cell lines. Autofluorescence was accessed by DIC imaging of each cell line,
and no autofluorescence was detected (Supplemental 1). A fluorescent signal was not
seen in control groups incubated with cANGPTL4 primary antibody but no secondary
antibody or vice versa. Furthermore, a signal was not seen in cells incubated with
fANGPTL4 or nANGPTL4 antibodies. This indicates that while cANGPTL4 associate
with cell surface proteins, fANGPTL4 and nANGPTL4 do not associate with cell surface
proteins. These results explain why fANGPTL4 and nANGPTL4 but not cANGPTL4
were found in the conditioned medium in the protein secretion analysis.
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Figure 3.4: Cellular localization of cANGPTL4 in pancreatic and breast cancer cells
using confocal microscopy. A) MDA-MB231 cells grown in hypoxia for 24 hours and
labeled with cANGPTL4 antibody; nuclei (blue) were stained with Nuc-blue, F-actin
(red) was stained with Actin-red 555, and cANGPTL4 (green) was stained with Alexa
Fluor 488. A merged image revealed cANGPTL4 secreted to the outside the cells. B)
Panc-1 cells grown in hypoxia for 24 hours and labeled with cANGPTL4 antibody;
nuclei (blue) were stained with Nuc-blue, F-actin (red) was stained with Actin-red 555,
and cANGPTL4 (green) was stained with Alexa Fluor 488. A merged image revealed
cANGPTL4 secreted to the outside the cells. Scale bar = 100µm.
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3.3.5 cANGPTL4 and integrin-b1
To gain insights into the interaction between cANGPTL4 and integrin b1, the
cellular location of each protein was examined using immunofluorescence with confocal
imaging. Once secreted to the cell surface, cANGPTL4 has been shown to facilitate
metastasis by disrupting endothelial barrier integrity when interacting with integrin 𝛼5ß1
(Huang et al., 2011). The binding affinity of cANGPTL4 to integrin b1 was determined
by surface plasmon resonance (SPR), but little is known about this interaction (Huang et
al., 2011). Immunofluorescence and confocal imaging of Panc-1 cells grown under
hypoxia shows colocalization of these proteins (Figure 3.5). Previous studies have shown
that cANGPTL4 first bind to integrin b1 before subsequently binding to VE-cadherin and
claudin-5 (Huang et al., 2011). These results are supportive showing that cANGPTL4 is
interacting with integrin b1 on the cell surface.

Figure 3.5: Cellular localization of cANGPTL4 and integrin-b1 in Panc-1cells using
immunofluorescence and confocal imaging. Panc-1 cells were grown to confluency
under hypoxia, then labeled with cANGPTL4 and integrin b1 antibody. Nuclei (blue)
were stained with Nuc-blue, cANGPTL4 (green) was stained with Alexa Fluor 488, and
integrin b1 was stained with Alexa Fluor 690. The last image is merged and shows
colocalization of cANGPTL4 with integrin b1. Scale bar = 100µm.
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3.4 Discussion
ANGPTL4 has been suggested to inhibit leaking in the vascular system, which in
turn inhibited extravasation of cancer cells (Ito et al., 2003). The molecular mass for
ANGPTL4 was not reported in the study so it is unknown if the full-length protein or one
of the two fragments was detected (Ito et al., 2003). In another study, fANGPTL4 and
cANGPTL4 were overexpressed in melanoma cells (Galaup et al., 2006). ANGPTL4
was shown to inhibit cancer cell metastasis, but the activity was not differentiated for the
f- and c form (Galaup et al., 2006)
Contradicting studies have shown that ANGPTL4 plays essential roles in the
different stages of proliferation, anoikis resistance, and metastasis (Zhu et al., 2011; Tan
et al., 2012). ANGPTL4 has been suggested to promote breast cancer metastasis to lung
tissue by increasing leaking in the vascular system. A knock-down of ANGPTL4
expression resulted in a significant decrease of breast cancer cell invasion (Padua et al.,
2008). Migration and metastasis of hepatocellular carcinoma was seen with increased
levels of ANGPTL4 expression (Li et al., 2011). Differential expression of ANGPTL4
have been correlated to poor survival rates of individuals diagnosed with gastric and
colorectal cancer. However, the underlying mechanisms of action and functions of the
different ANGPTL4 isoforms are not known. In this chapter, we provided insight into
the expression and secretion of these isoforms.
Expression and secretion of fANGPTL4, nANGPTL4, and cANGPTL4 in three
pancreatic and three breast cancer cell lines was examined under normoxia and hypoxia.
No protein secretion was detected for any cell line under normoxia. fANGPTL4 was
secreted by two pancreatic (Panc-1, Capan-1) and all three breast cancer cells (MDA-
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MB231, MCF7, and SKBR3) cultured under hypoxia. Two sets of pancreatic cancer
lines secreted nANGPTL4 (MiaPaCa2 and Capan-1), but cANGPTL4 was not detected in
any of the conditioned medium. Only the Capan-1 cells secreted both fANGPTL4 and
nANGPTL4. Hypoxia induced expression of ANGPTL4 RNA was observed in the six
cancer cell lines, but not in HEK293 cells used as a control. Panc-1 and MDA-MB231
cells exhibited the largest increase in expression of ANGPTL4. While expression levels
of ANGPTL4 did significantly increase in all cancer cells, cellular proliferation rates did
not increase for any of the cell lines.
ANGPTL4 belongs to a family of proteins involved in angiogenesis, the process
in which proliferation of endothelial cells leads to the formation of new blood vessels
(Tan et al., 2012). This is essential for tumor growth and metastasis. Expression levels
of proangiogenic cytokines and enzymes, like cyclooxygenase 2 (COX2), have been used
in assessing the angiogenic potential of cancer cells (Sobolewski et al., 2010). COX2
expression has been detected in Capan-1 and Capan-2, but not detected in MiaPaCa2 or
Panc-1 cell lines (Deer et al., 2010). Prostaglandin E2 is a product of COX2 that has
been indicated to have a tumorigenic role. Capan-1 cells exhibited the third largest
increase in ANGPTL4 expression under hypoxia, and they were the only cells to secrete
both fANGPTL4 and nANGPTL4. It has been suggested that prostaglandin E2 and
hypoxia enhance ANGPTL4 expression and cANGPTL4 secretion. Also, Capan-1 cells
possess a mutation and do not express SMAD4/DPC4, a tumor suppressor and a member
of the transforming growth factor family (Deer et al., 2010). The overall aggressiveness
of PDAC cells has been linked to angiogenesis, and these results show that Capan-1 cells
have high angiogenic potential (Deer et al., 2010).
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ANGPTL4 full length protein, along with nANGPTL4 and cANGPTL4, can be
found in blood plasms and many tissues (Zhang et al., 2017). Few studies have
demonstrated a structure-function relationship for these isoforms. However, cANGPTL4
has been associated with anoikis resistance, the ability of cancer cells to escape apoptosis
after disconnection from the extracellular matrix (Tan et al., 2012; Tjeerdema et al.,
2014). This isoform has been shown to interact with multiple beta-integrins elevating
cellular levels of ROS (Terada and Nwariaku, 2011). Increased cellular levels of ROS
are also seen with chronic ER stress. Previous studies have demonstrated that sustained
increases in ROS levels are involved in the initiation and progression of aggressive
tumors (La Paglia et al., 2017). We show that cANGPTL4 does interact with integrin b1
on the surface of Panc-1 cell when cultured under hypoxic conditions. These results
support the idea that cANGPTL4 and its interactions play a role in cancer cell
progression.
The metastatic capacity of PDAC highlights the importance of understanding cell
adhesion. This property influences tumor growth and influences metastasis. Cell
adhesion is mediated by the interactions of surface molecules with the extracellular
matrix (Chong et al., 2012). Panc-1 and Capan-1 cells have demonstrated tight
adherence to a mixture of components (Deer et al., 2010). Panc-1 cells exhibited the
strongest adherence to collagen I, II, IV, and fibronectin. Cellular localization of
fANGPTL4, nANGPTL4, and cANGPTL4 was investigated using immunofluorescent
labeling and confocal imaging in Panc-1 and MDA-MB231 cells since they exhibited the
greatest increase in ANGPTL4 expression under hypoxia. cANGPTL4 was identified on
the extracellular matrix of Panc-1 and MDA-MB231 cells, but a fluorescent signal was
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not detected in any of the samples probed for fANGPTL4 or nANGPTL4. Furthermore,
colocalization of cANGPTL4 and integrin-β1 was seen in Panc-1 cells. In a previous
study, cANGPTL4 induced vascular disruption through a direct and sequential
association with integrin α5β1, E-cadherin, and claudin-5 (Huang et al., 2011). We
provide supportive evidence that demonstrated cANGPTL4 interacted with integrin b1.
Using immunofluorescence and confocal imaging, colocalization of these proteins was
seen on the surface of Panc-1 cells cultured under hypoxic conditions. These results
highlight the significance of future structural studies examining which cANGTPTL4
residues interact with integrin b1.
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Chapter 4

Crystallographic Derived Structures of Angiopoietin-like 4’s Carboxy-Terminal
Domain Reveal a Binding Site for Multiple Ligands

4.1 Introduction
ANGPTL4 has been identified as a secreted protein affecting cell-matrix
communication. It interacts with extracellular vitronectin and fibronectin.
ANGPTL4 has shown to play a novel role in wound healing. It binds to integrin b1
and b5 on keratinocytes aiding in wound closure by re-epithelialization. Natural
wound healing shares similarities with tumor progression such as inflammation,
matrix remodeling, and cell migration (Goh et al., 2010). Furthermore, studies have
indicated that cANGPTL4 interacts with integrin α5β1, VE-cadherin and claudin-5 to
disrupt endothelial continuity through integrin-mediated PAK/Rac signaling (Huang et
al., 2011). However, a full list of this protein’s interacting partners is not available.
The human ANGPTL4 gene encodes a 45–65 kDa protein that is well conserved
among various species (Yang et al., 2008). Reported molecular masses vary due to
different isoforms and glycosylation. This protein undergoes posttranslational
modifications resulting in an amino-terminal coiled-coil domain (nANGPTL4), and a
carboxy-terminal fibrinogen-like domain (cANGPTL4). The cleavage site and
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function are tissue dependent (Lei et al., 2011). In mouse melanoma cells, a protein
fragment with an equivalent molecular mass as cANGPTL4 was revealed after
expression of ANGPTL4 (Galaup et al., 2006). In a study of major epithelial tumors,
like squamous cell carcinoma, only cANGPTL4 was found to be overexpressed (Tan
et al., 2012).
The binding of nANGPTL4 to lipoprotein lipase (LPL) has been well studied
and demonstrated repeatedly (Sukonina et al., 2006; Mysling et al., 2016; Wang and
Eckel, 2009; Chi et al., 2015). Through the binding of its N-terminal coiled-coil
domain to LPL, this protein is a regulator of plasma triglycerides. Additionally, it
has been demonstrated that fatty acids act to reduce nANGPTL4’s effect of LPL
activity (Chi et al., 2015). Fatty acids that produced this effect were oleic acid,
palmitic acid, myristic acid, and linoleic acid. These fatty acids were found to have a
high affinity and bind to nANGPTL4 as determined by surface plasmon resonance,
isothermal titration calorimetry, and fluorescent studies (Robal et al., 2012).
However, there was no mention of a study examining fatty acid binding to
cANGPTL4.
Cancer cells have been shown to regulate cell signaling to stimulate the
process of lipid biosynthesis to support continuous cellular proliferation (Phan et al.,
2014). A major metabolic event in cancer progression is the activation of fatty acid
synthesis, which results in the production of saturated fatty acids (SFA) as well as
monounsaturated fatty acids (MUFA). This provides the cells with much needed
energy and sustains the demand for phospholipids required for new cell membranes
(Igal, 2010). A more comprehensive understanding is needed concerning this
process as well as investigations studying the binding of biomolecules to SFAs.
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There are many genetic alterations in cells that lead to disturbances in
mechanisms that control cell division, cell death, and cell metabolism (Elmore,
2007). Malignant cells have a different metabolic activity than normal cells. They
establish metabolic reprogramming in order to meet their substantial energy
requirements. These cells show an increased uptake of glucose and fatty acid
production. Research has implicated complex carbohydrates in cell adhesion
processes, cell adhesion to the extracellular matrix, and cell-cell recognition.
Furthermore, carbohydrates can hinder cell adhesion processes as well a cell-cell
recognition (Nangia-Makker et al., 2002).
A more comprehensive understanding is needed on the various functions of
each domain to understand which fragments actually play an active role in the
progression of cancer cells (Tan et al., 2012). Also, information concerning
posttranslational modifications and molecular mass vary for each fragment. These
data are important when investigated protein binding. Studies have demonstrated
that cANGPTL4 interacts with integrin α5β1, VE-cadherin and claudin-5 (Huang et al.,
2011). Previous studies have shown that nANGPTL4 binds to fatty acids such as
oleic acid, palmitic acid, myristic acid, and linoleic acid. However, it is cANGPTL4
that has been associated with angiogenesis, cancer cell invasiveness, increased cellular
proliferation, cell migration, and cell adhesion (Tan et al., 2012; Zhu et al., 2011).
ANGPTL4 has been shown to play a role in the progression of numerous
types of cancers, including PDAC (Tan et al., 2012; Kirbya et al., 2016; Galaup et al.,
2006). The research described here is an examination of the structural properties of
cANGPTL4. There is a discrepancy among previous studies concerning the reported
molecular mass of ANGPTL4 (Tan et al., 2012). The most likely reason is variation in
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cleavage forms and glycosylation that as a result of tissue dependence (Tan et al., 2012).
Both glycosylated and non-glycosylated cANGPTL4 have been reported (Grootaert et al.,
2012). Also, it is known that fatty acids bind to nANGPTL4, but it is unknown if fatty
acid bind to cANGPTL4 (Robal et al., 2012). In fact, a repertoire of this protein’s
interacting partners remains to be determined. We use X-ray crystallography and
binding studies to obtain insight into the structural properties of cANGPTL4.

4.2 Material and Methods

4.2.1 Expression and Purification of Recombinant Human cANGPTL4
The amino acid sequence of cANGPTL4 from various species was obtained from
UniProt, aligned using Clustal Omega and evaluated for conserved residues. An
expression plasmid was assembled from oligos using DNA Works at Helix System for
human cANGPTL4 (185-406) with an N-terminal His6-tag. The plasmid was cloned into
the NdeI and BamHI sites of pET3a (Novagen, USA) through homologous
recombination. The plasmid was propagated in Escherichia coli strain DH5α cells
(Genlantis, Inc. San Diego, CA), error-free clones were further selected by DNA
sequencing (Eurofin, AL, USA), and were transformed into E. coli SHuffle cells
(Genlantis, Inc., CA, USA) for protein expression. E. coli cells harboring an expression
construct were grown in 1 liter of Luria-Bertani (LB) medium containing 500 µl of 100
mg/ml carbenicillin (50 µg/ml final concentration) at 30°C overnight with constant
shaking at 250 rpm. The cell starter culture was centrifuged at 6000 rpm for six minutes,
and the cell pellets were re-suspended in 50 mL of LB. Re-suspended cells were added
to a 10 L terrific broth medium containing carbenicillin in a bioreactor with continuous
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aeriation. Cells were cultured until an OD600 of 0.6 was reached, and then induced by
adding isopropyl β-D-galactopyranoside (IPTG) to a final concentration of 0.6 mM to
express the recombinant protein. Induction was maintained for 12 hours at 18°C with
continuous aeration. Bacterial cells were harvested by centrifugation at 6000 rpm at 4°C
for six minutes and stored at -80°C.
A 25 g cell pellet was re-suspended in lysis buffer consists of 50 mM Bis-Trispropane pH 9.2, 20 mM imidazole, and 400 mM NaCl for protein isolation purification.
After lysis and centrifugation at 17,000 g for 45 minutes, the protein was purified using a
nickel affinity column equilibrated with the same buffer solution. The column was
washed with lysis buffer, and protein was eluted from the column using lysis buffer
containing an increased concentration of imidazole (375 mM). Protein purity was
evaluated on a 12% Bis-Tris gel and Coomassie stain. Concentrated protein was further
purified using size exclusion chromatography (S200) with 50 mM Bis-Tris-propane and
100 mM NaCl, pH 9.2. An Amicon Ultra 10K spin column was used to concentrate the
protein to 12 mg/mL and it was stored at 4°C. Protein purity and sequence were
confirmed by mass spectrometry.

4.2.2 Proliferation Assay with Recombinant Human cANGPTL4
The biological activity of recombinant cANGPTL4 was measured with a cell
proliferation assay. Panc-1, MiaPaCa2, and BxPC3 grown in cell culture were
transfected in duplicate samples with 1 ng/µL and 10 ng/µL of recombinant cANGPTL4
using Xfect Protein Transfection Reagent (Clontech). The assay was repeated with the
addition of 20uM Diphenyleneiodonium (an inhibitor of NADPH oxidase). Cells from
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each line were also transfected with GFP control at 1 ng/µL and 10 ng/µL. The number
of viable cells in culture 12 hours post-transfection were determined with CellTiter-Glo
Luminescent Cell Viability Assay (Promega).

4.2.3 Crystallization Screening

Approximately 2 mL of cANGPTL4 at 11 mg/mL was trace ﬂuorescently labeled
with carboxyrhodamine-succinimidyl ester for visualization of protein crystals in
crystallization plates (Invitrogen) (Forsythe et al., 2006). Sitting-drop vapor diffusion
screening was used by adding 50 µl of solution to reservoirs and protein to precipitate
volumes of 2:1, 1:1 and 1:2 into 96-well plates (Hampton Research). In order to
maximize the likelihood of obtaining crystals, this process was completed using three
commercial screens: HRHT (Hampton Research), JCSG+ (Molecular Dimensions), and
MCSG-3 (Anatrace). A fourth screen was setup using an in-house devised 96 condition
crystallization screen with more instances of precipitants that appear only a few times in
commercial screens. Plates were scanned daily using fluorescence with a Crystal X2
imaging device to look for the formation of protein crystals. Crystals were identified by
their having a high fluorescence intensity relative to precipitated protein. Starting
crystallization conditions were identified as 0.1 M HEPES, 1.6 M ammonium sulfate, 0.1
M sodium chloride, pH 7.5. Screening around these conditions was carried out by
varying the ammonium sulfate concentration and the buffer pH. Improved conditions,
used for ligand binding studies, were found to be over the pH range of 7.5 to 7.7, with
ammonium sulfate reservoir concentrations ranging from 0.9 M to 1.2 M.
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Ligand binding studies were set up in 4 x 4 blocks of wells in the 96 well sitting
drop plates, with the pH varying from 7.5 to 7.7 in the X-axis and ammonium sulfate
from 1.2 to 0.9 M in the Y-axis. Six blocks were set up for each 96 well plate. Ligand
binding crystallization plates were set up by hand. Fatty acid ligands tested included
butyric, myristic, palmitic, stearic palmitoleic, oleic, linoleic, and arachidonic acids.
Carbohydrate ligands tested included glucose, fructose, sucrose, lactose, arabinose,
mannose, and ribose. One 4x4 well block of each plate was used for growing ligand-free
crystals for comparison. The fatty acid ligands were taken up in ethanol, then each was
added to the protein solution in an equimolar ratio. The carbohydrates were taken up in
dH2O and added to the protein solution at a 10:1 (ligand:protein) ratio. The starting
protein solution concentration was 11 mg/mL in the final gel filtration buffer (0.025 M
Bis-Tris Propane, 0.2 M NaCl, pH 9.5). The crystals obtained at the lower ammonium
sulfate concentrations were typically best for collecting diffraction data.
Crystals were harvested using appropriate loop sizes (MiTeGen), then briefly
soaked in a cryoprotectant solution containing reservoir solution. Glycerol was initially
used, at 20%, but it was discontinued once it was found in the ligand binding pocket due
to concerns that it could displace the fatty acid ligands. Ethylene glycol was
subsequently employed at 20% concentration as the cryoprotectant.

4.2.4 Diffraction Data and Structure Elucidation
Diffraction data were collected at Argonne National Lab on beamline SBC-CAT
on 19BM or ID. Diffraction images were integrated and scaled using HKL 2000 and
3000. Phenix (version 1.16.1) was used to obtain phasing. Molecular replacement was
performed in Phenix. Then, molecular replacement was repeated using a different
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structure from the PDB for two sets of diffraction data as a comparison. Protein structure
model building and refinement was completed using both Phenix (Adams et al., 2002)
and COOT (Crystallographic Object-Oriented Toolkit) crystallographic software.
X-ray diffraction data were collected, images were indexed, and integration was
completed using DENZO. Once integrated, diffraction data were scaled with the
SCALEPACK program in HKL 2000 or 3000. Crystallographic resolution was cutoff at
an I/s value greater than 2. Scaled intensities were converted to structure factors. Files
were transferred to Phenix for phasing and elucidation of structures.
Phasing was complete in Phenix using molecular replacement with PHASER.
Molecular replacement was performed in Phenix using PDB 1Z3S as a model for the first
crystallographic structure. Then, PDB 6EUB was used as a molecular replacement model
for two sets of diffraction data as a comparison. Each structure underwent refinement
using Phenix: refine. COOT crystallographic software was used to visualize the Fo-Fc
and 2Fo-Fc electron density maps and manually fit residues or ligands. Three high
resolution crystallographic derived structures were determined and deposited in the
protein data bank.

4.2.5 Palmitic Acid and cANGPTL4 Binding Assay
Capan-1 cells expressing cANGPTL4 were grown on hydrophilic, tissue culturetreated ibidi 8-well microchamber plates. Cells were grown to approximately 80%
confluency. Capan-1 cells in 2 of the 8 wells were incubated with BODIPY (4,4difluoro-4-bora-3a,4a-diaza-s-indacene) tagged palmitic acid, cells in 2 wells were
incubated with fluorescently-labeled recombinant cANGPTL4 combined with BODIPY
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(4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) tagged palmitic acid, cells in 2 wells were
incubated with fluorescently-labeled recombinant cANGPTL4 without palmitic acid, and
serum free media only was placed in the final 2 wells. Cells were incubated at 37° C for
3 hours. Following incubation, unbound palmitic acid and recombinant cANGPTL4 were
removed by washing extensively with PBS. Cells were fixed with 4% paraformaldehyde
for 10 minutes. They were washed three times in PBS, briefly washed with 0.1M
ammonium chloride, washed again with PBS, and blocked with 3% normal goat serum
for 1 h at room temperature. Following three washes in PBS, cells in the 2 wells that
were incubated with fluorescently labeled palmitic acid were incubated overnight at 4 °C
with anti-human cANGPTL4. Cells in the rest of the wells were left in 3% normal goat
serum during this time. After three washes with PBS at room temperature, cells were
incubated with Alexa Fluor 647 secondary antibodies for 2 hours. Actin-red 555 and
Nuc-blue were added for actin and nuclear staining. Imaging was performed without
primary antibodies served as negative controls. Images were acquired using a Zeiss
LSM710 confocal microscope.

4.2.6 Thermal Shift Assay to Determine Kd for Palmitic Acid Binding
Thermal shift assays were performed to measure the binding of palmitic acid and
cANGPTL4 using a Tycho NT.6 from Nanotemper (Adams et al., 2016). Use of this
instrument was kindly provided by PMI BioPharma Solutions (Nashville, TN). Briefly,
the assay was carried out by mixing cANGPT4 in a buffer consisting of 0.05M HEPES,
0.2M NaCl, pH 7.5 with palmitic acid solution in (solvent), such that the final
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concentration was fixed at 25% while the palmitic acid varied between 0.2 µM and 25
µM. Assays were carried out at cANGPTL4 concentrations of 0.25 and 1.0 µM.

4.3 Results
4.3.1 Protein Analysis
To examine the purity of recombinant human cANGPTL4, the protein was
analyzed by SDS-PAGE with Coomassie blue staining (Supplemental 2A). A protein
band was obtained at the expected molecular weight at approximately 26,600 kDa. To
confirm the protein sequence, a sample was sent to the University of Alabama in
Birmingham for mass spectrometry analysis. Results identified the sequence of residues
185 - 400 of ANGPTL4’s C-terminal domain (Supplemental 2B).

4.3.2 Biological activity
To determine if the recombinant protein was active, a cellular proliferation assay
was performed. Low concentrations (1 ng/µL and 10 ng/µL) of protein were transfected
into Panc-1, MiaPaCa2, and BxPC3 grown in cell culture. A two-tailed T-test was
performed to determine statistical significance. Cellular proliferation rates were not
significantly increased in Panc-1 cells transfected with 1 ng/µL of protein but were
increased in cells transfected with 10 ng/µL (p = 0.05) (Figure 4.1). Cellular proliferation
rates were significantly increased in MiaPaCa2 cells transfected with 1 ng/µL (p = 0.023)
and 10 ng/µL (p = 0.0081). No significant increase in cellular proliferation was seen in
BxPC3 cells.
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Figure 4.1: Box plots depicting cellular proliferation rates of Panc-1, MiaPaCa2, and
BxPC3 cells post-transfection with recombinant human cANGPTL4. Recombinant
human cANGPTL4 protein was transfected into cells at 1 ng/µL and 10 ng/µL protein.
Number of viable cells were determined 12 hours post-transfection with CellTiter-Glo
Luminescent Cell Viability Assay.

4.3.3 Protein Crystals
In order to screen for crystallization conditions, cANGPTL4 at 11 mg/mL was
trace ﬂuorescently labeled with carboxyrhodamine-succinimidyl ester and used in
multiple crystallization screens. Thin plate-shaped protein crystals formed in a well
containing 0.1 M HEPES pH 7.5, 0.1 M sodium chloride, and 1.6 M ammonium sulfate
(Figure 4.2). Once crystallization conditions were identified, additional sitting-drop
vapor diffusion plates were created with the addition of various unsaturated fatty acids,
saturated fatty acids, and carbohydrates. Crystals were found in wells containing protein
plus myristic, palmitic, oleic, linoleic, or stearic acid.
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Figure 4.2: Protein crystals of recombinant human cANGPTL4. A) Thin plate-shaped
crystals of recombinant human cANGPTL4 formed in a well containing 0.1 M HEPES
pH 7.5, 0.1 M sodium chloride, and 1.6 M ammonium sulfate. B) Crystals of recombinant
human cANGPTL4 formed in a well containing 0.1 M HEPES pH 7.5, 0.1 M sodium
chloride, 1.6 M ammonium sulfate, and palmitic or myristic acid. Scale is microns per
smallest division.

4.3.4 Protein Structure of Recombinant Human cANGPTL4 Monomer
To analyze the amino acid sequence of cANGPTL4 (180-400), Clustal Omega
was used to align the sequences from various species. The analysis showed similarities
and several well conserved residues between them (Figure 4.3). There are 4 well
conserved cysteine residues at C188, C216, C341, and C354. The monomeric structure
of cANGPTL4 has a topology of a1-b1-b2-b3-a2-b4-b5-b6-b7-h1-b8-a4-b9-a5-b1072

h2-b11-b12 (Figure 4.4). It is stabilized by two disulfide bonds formed by C188 - C216
and C341 - C354 (Figure 4.5). The recombinant cANGPTL4 protein was designed to
begin with P185 and end with M400.

Figure 4.3: Analysis of the amino acid sequence of cANGPTL4 (180-400) shows
similarities and conserved residues between various species. There are 4 well conserved
cysteine residues at C188, C216, C341, and C354.
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Figure 4.4: Monomeric structure of recombinant human cANGPTL4 showing a1-b1-b2b3-a2-b4-b5-b6-b7-h1-b8-a4-b9-a5-b10-h2-b11-b12 topology. Each secondary
structure element is colored as cyan for a-helices, fuchsia for b strands, and pink for
loops.

Figure 4.5: Atomic resolution image of 4 conserved cysteine residues in cANGPTL4. A)
Disulfide bond between C188 and C216 B) Disulfide bond between C341 and C354. The
2Fo-Fc electron density maps were contoured at 1s.
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4.3.5 Glycerol Binding to cANGPTL4
cANGPTL4 protein crystallized with one molecule in the asymmetric unit (Table
4.1). The electron density map contained peaks near Trp349, Trp350, His356, and
Ser357. The crystal structure of cANGPTL4 in complex with glycerol was solved to a
crystallographic resolution of 2.11Å in a C2221 space group. Molecular replacement was
used to solve the structure, and it was refined to R/Rfree values of 21.3/23.6. A glycerol
molecule forms a hydrogen bond with Trp349, Trp350, His356, Ser357 (Figure 4.6).
Coordinates were deposited in the PDB with the accession ID 6U0A.

4.3.6 Palmitic Acid Binding to cANGPTL4
Crystals of the cANGPTL4/palmitic acid complex grew in the same C2221 space
group. The monomeric structure was solved to a 1.75 Å resolution and refined to R/Rfree
values of 19.4/21.1 (Table 4.2). The carboxylic head of palmitic acid forms a hydrogen
bond with Thr353 while hydrophobic side chains of amino acids in the binding pocket
stabilize the alkyl tail by van der Waals interactions. Previous experiments of fatty acid
binding protein 5 (FABP5) have resulted in an enlargement of the ligand pocket volume
as a fatty acid would bind to Cys127. The electron density of the cANGPTL4/palmitic
acid complex reveals the unequivocal presence of disulfide bonds between Cys341 and
Cys354 (Figure 4.7). Coordinates were deposited in the PDB with the accession ID
6U1U.
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Table 4.1: Refinement statistics for crystal structure of recombinant human cANGPTL4
with glycerol, PDB ID 6U0A.
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Figure 4.6: Structural analysis of cANGPTL4 binding pocket with glycerol. Glycerol
forms a hydrogen bond with Trp349, Trp350, His356, Ser357. The 2Fo-Fc electron
density maps were contoured at 1s.
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Table 4.2: Refinement statistics for crystal structure of recombinant human cANGPTL4
with palmitic acid, PDB ID 6U1U.
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Figure 4.7: Structural analysis of cANGPTL4 binding pocket with palmitic acid.
The carboxylic head of palmitic acid forms a hydrogen bond with Thr353 while
hydrophobic side chains of amino acids in the binding pocket stabilize the alkyl tail by
van der Waals interactions. B) Electron density map showing a disulfide bond between
Cys341 and Cys354. The 2Fo-Fc electron density maps were contoured at 1s.

4.3.7 Myristic Acid Binding to cANGPTL4
Myristic acid is another long chain saturated fatty acid that was added to
cANGPTL4 in crystallization trials. A space group of C2221 was once again obtained,
and the monomeric structure was solved to a resolution of 2.37 Å. The structure was
refined to R/Rfree values of 19.4/23.8 (Table 4.3). Once again, the carboxylic head of
palmitic acid forms a hydrogen bond with Thr353 while the alkyl tail is stabilized by van
der Waals interactions (Figure 4.8). Coordinates were deposited in the PDB with the
accession ID 6U73.
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Table 4.3: Refinement statistics for crystal structure of recombinant human cANGPTL4
with myristic acid, PDB ID 6U73.
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Figure 4.8: Structural analysis of cANGPTL4 binding pocket with myristic acid. The
carboxylic head of palmitic acid forms a hydrogen bond with Thr353 while hydrophobic
side chains of amino acids in the binding pocket stabilize the alkyl tail by van der Waals
interactions. Electron density map showing a disulfide bond between Cys341 and
Cys354. The 2Fo-Fc electron density maps were contoured at 1s.
4.3.8 Binding of cANGPTL4 to Palmitic Acid Cell Culture Assay
In order to examine cANGPTL4 binding to palmitic acid and cellular location of
the complex, Capan-1 cells were incubated with BODIPY (4,4-difluoro-4-bora-3a,4adiaza-s-indacene) tagged palmitic acid and lucifer yellow tagged recombinant
cANGPTL4 in serum free media. Images obtained with confocal microscopy showed
cells with cANGPTL4 (yellow), cells with palmitic acid (green), and cells with both
molecules. A merged image reveals both cANGPTL4 and palmitic acid colocalized
inside Capan-1 cells (Figure 4.9, top panel). No autofluorescence was seen in DIC
imaging of these cells.
In order to investigate the binding of palmitic acid to endogenous cANGPTL4,
Capan-1 cells were incubated with only BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-
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indacene) tagged palmitic acid for 3 hours. Then the cells were incubated with Actin-red
555 and Nuc-blue. Images obtained with confocal microscopy showed the nuclei (blue),
actin filaments (red), and palmitic acid (green) located inside Capan-1 cells. Fatty acids,
like palmitic acid, would remain outside cells without being bought into the cells by a
transporter, such as cANGPTL4 (Figure 4.9, bottom panel).

Figure 4.9: Examining the binding of palmitic acid and cANGPTL4 in Capan-1 cells.
Top panel: Capan-1 cells incubated with BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-sindacene) tagged palmitic acid and lucifer yellow tagged recombinant cANGPTL4 in
serum free medium. DIC image shows no autofluorescence in the first image. The
second image shows cells with cANGPTL4 (yellow), third image shows cells with
palmitic acid (green), and fourth image shows cells with cANGPTL4 and palmitic acid
inside the cells. Bottom panel: Capan-1 cells incubated with only BODIPY (4,4-difluoro4-bora-3a,4a-diaza-s-indacene) tagged palmitic acid, Actin-red 555, and Nuc-blue. The
first image shows nuclei only, second image shows cells with cANGPTL4 (yellow), third
image shows cells with palmitic acid (green), and the fourth image shows cells with
cANGPTL4 and palmitic acid inside the cells.
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4.3.9 Binding of cANGPTL4 to Palmitic Acid Thermal Shift Assay

Having found palmitic acid bound to the cANGPTL4, the binding affinity of the
fatty acid to the protein was determined using a thermal shift assay. This assay was
performed using a Tycho NT.6 from Nanotemper courtesy of PMI BioPharma Solutions
(Nashville, TN) (Adams et al., 2016). The principle of the assay is that the protein, in the
presence of varying concentrations of ligand, is heated from 35 to 90 °C and the intrinsic
fluorescence emission at 330 and 350 nm measured as a function of temperature. The
350/330 ratio changes as the protein unfolds, and the midpoint of the ratio curve vs.
temperature is plotted as a function of the ligand concentration. Bound ligand that
stabilizes the protein structure shifts the midpoint to a higher concentration, and a plot of
the midpoint vs. ligand concentration can be used to estimate the binding constant of the
ligand for the protein. The binding of palmitic acid to cANGPTL4 was evaluated at two
protein concentrations, 0.25 and 1.0 µM, and over the range of palmitic acid
concentrations from 0.2 to 25 µM. The experiments were carried out in duplicate. The
results indicated a Kd ranging from 0.77 to 1.3 µM at a protein concentration of 1.0 µM
(Figure 4.10 and Table 4.4). This value is well within the range of the plasma free
palmitic acid concentration, which ranges from 0.3 to 4.1 mmol/L in healthy adults
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Figure 4.10: Thermal shift assay measuring the binding of palmitic acid and cANGPTL4
at 0.25 µM and 1.0 µM using a Tycho NT.6 from Nanotemper.

Table 4.4: Thermal shift assay measuring the binding of palmitic acid and cANGPTL4 at
0.25 µM and 1.0 µM using a Tycho NT.6 from Nanotemper.
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4.4 Discussion
ANGPTL4 is a secreted protein known to play a role in the progression of
multiple carcinomas (Tan et al., 2012; Zhu et al., 2011; Huang et al., 2011; Kirbya et al.,
2016; Kim et al., 2000). This protein has been implicated in the metabolic
reprogramming of cancer cells during EMT (Teo et al., 2017). A decline in cellular
energy resulting in decreased metastasis was seen in cancer cells lacking ANGPTL4
during EMT. Additionally, it was shown that ANGPTL4 controlled the expression of
certain 14-3-3 proteins to meet cellular energy requirements for EMT. Previous
investigations revealed that ANGPTL4 promoted anoikis resistance and tumor growth by
triggering a 14-3-3 adapter protein, which isolated apoptotic proteins (Teo et al., 2017).
However, how ANGPTL4 controls the expression of 14-3-3 and triggers the adapter
protein remains unknown. Our crystallographic derived models reveal a common
binding site for multiple ligands (deposited in the PDB as IDs 6U0A, 6U1U, and 6U73).
While we do not show ANGPTL4 in complex with a 14-3-3 protein, we do show
cANGPTL4 in complex with glycerol and fatty acids. This provides considerable insight
into how cANGPTL4 can provide cancer cells with energy necessary for proliferation
and EMT.
The regulation of lipid and glucose metabolism is a well-established function of
ANGPTL4 (Xu et al., 2005; Sukonina et al. 2006). The protein has also been associated
with diabetes, coronary artery disease, and obesity (Tan et al., 2012; Zhu et al., 2011).
Cancer cells are known to undergo metabolic reprogramming to meet energy
requirements, and ANGPTL4 has been recognized as a controller of this reprogramming
(Teo et al., 2017). This study investigated the fragment cANGPTL4 in PDA. Our
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findings provide novel insight into cANGPTL4’s metabolic role by showing for the first
time how this protein may transport palmitic acid into pancreatic cancer cells.
Palmitic acid binding by cANGPTL4 was found to be in the low µM range, at a
level consistent with free plasma concentrations. The binding site was also occupied by
glycerol in another crystallographic derived structure (Deposited as PDB ID 6U0A).
There is a possibility that this site could accommodate a mono- or a di-glyceride.
Crystals have been obtained for cANGPTL4 grown in the presence of mono-myristin, but
diffraction data has not been collected or processed for them at this time.
cANGPTL4 has been reported as both glycosylated and non-glycosylated,
depending on the expressing tissue (Tan et al., 2012; Zhu et al., 2011). While we were
not able to verify this due to corrupted data, we were able to show that the nonglycosylated recombinant protein behaved similarly to the endogenous protein in terms of
binding to integrin-b1, thus indicating that glycosylation is presumably not required for
this function. Additionally, we found that the recombinant protein binds to fatty acids
and glycerol, and that it then transports the fatty acids into the cell. Again,
immunofluorescence and confocal microscopy studies show that the endogenous protein
also binds to and transports fatty acids into the cell. The fatty acid binding function of
cANGPTL4 is a novel finding of this research, revealing a hitherto unknown function and
role for the protein. Further, while studies with the un-liganded protein show that it is
located on the extracellular matrix, the fatty acid liganded protein is not located there, but
rather inside the cell. Thus, the binding of fatty acids serves to redirect the protein to a
new role, the potential of which remains to be explored. This may well indicate a
therapeutic function that can be exploited through the design of a pharmaceutical that
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binds to the fatty acid binding of cANGPTL4 to deliver it to cancer tumors. While nontrivial, this could potentially bypass the problem of a general targeting of cANGPTL4
which could result in the disruption of other needed cellular functions in which it
participates.
Since cANGPTL4 is a multifunctional protein, and it is not unreasonable to
hypothesize that the protein-fatty acid complex also has a signaling function. What that
signaling function would be is not known and was not revealed in this research. This is
an important area for understanding any potential side effects associated with
pharmaceuticals developed to bind to the protein. Also, the signaling may not be directly
related to cancer progression, but rather may be linked to one of cANGPYL4’s other
functions. For example, the nANGPTL4 is known to affect lipoprotein lipase activity.
As the cANGPTL4 is binding a fatty acid, it is not unreasonable to suggest that the
signaling function is connected to regulation of fatty acid metabolism, and not directly to
cancer progression.
If a signaling function were present, then a starting point to explore the nature of
that function would be a pull-down assay. The work presented herein shows that
glycosylation is apparently not relevant to the fatty acid binding and transport therefore
this assay is simplified and can be carried out using non-glycosylated recombinant
protein. On the basis of the immunofluorescence in this study, the protein-fatty acid
complex is pulled into the cytoplasm. A pull-down assay would use cell cytoplasm
isolates with added either bare or fatty acid bound cANGPYL4. After pull-down the
proteins bound to the cANGPTL4 would be identified by 2D electrophoresis followed by
sequencing. The sequence information would reveal protein(s) that the cANGPTL4 is
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binding to, and thus what internal pathways are being impacted. There may be no
difference between liganded and unliganded cANGPYL4 in the pulled down binding
partners. This would not be surprising, as the unbound protein stays on the cell surface
and is not expected to be internalized.
In this study, we provide insight into cANGPTL4’s structure and function. These
results reveal a novel function of this protein and suggest how it may aid in cancer cell
progression. As discussed above, additional investigations are needed. Protein structures
are now available for use in future studies of cANGPTL4.
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Chapter 5

5.1 Summary

PDAC has a relative five-year survival rate of 34% with early stage diagnoses that
drops to 3% with metastasis (Noone et al., 2017). ANGPTL4 studied in detail here has
been indicated in the progression of this cancer and various others (Tan et al., 2012; Zhu
et al., 2012; Huang et al., 2011; Kirbya et al., 2016). There were three specific aims for
this research. First, to understand how cANGPTL4 expression drives malignant
phenotype. Second, to extend the existing structural-function studies from bacterially
produced to human cancer cells. Third to determine the specific residues of cANGPTL4
that interact with binding partners. For the first aim, we examined differential expression
of ANGPTL4 in pancreatic and breast cancer cell lines with varying phenotypical
characteristics. For the second aim, we investigated the secretion and cellular location of
full-length ANGPTL4 and both isoforms. We explored the interaction of endogenous
cANGPTL4 with integrin β1 and palmitic acid. Finally, we determined structures of
cANGPTL4 protein complexed to glycerol, palmitic acid, and myristic acid. This
allowed us to determine specific residues of cANGPTL4 that interacted with each.
Through a combination of these complimentary biochemical and biophysical
techniques, this work shows for the first time that cANGPTL4 binds fatty acids, a
previously unknown property of this protein. Further, the results show that the protein
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then carries the bound fatty acid back into the cell. This may be a means of supplying
energy to the cell, needed for the rapid growth and proliferation of cancer cells but also
may have a signaling function.

5.2 Future Studies
The research addressed much of the specific aims but leaves some details
unknown. For example, we do not know the role or roles of the cANGPTL4-fatty acid
complex. Experimentally, this could be explored adding the recombinant cANGPTL4fatty acid complex to a cell culture, briefly incubating them, washing the cells, then
lysing them, and thereby recovering the cANGPTL4 with any bound proteins using a
pull-down assay. This would provide information on any complex formed together with
a sample of that complex. Further work would be needed to determine the function, but
this would provide a suitable starting point for that direction. Alternatively, as the protein
in our case is already Hexa-His tagged it may be sufficient to pass the lysed cells
supernatant over a Ni++ affinity column. A similar analysis could then be used to
determine any complexes found. This was not done with the present work as they
exceeded our original goals but are a question for the future.
cANGPTL4 binds to a range of fatty acids but we have limited structural
knowledge on how this occurs. This should also be further explored. Crystals have been
obtained in the presence of the monoglyceride monomyristin, stearic acid, dodecanoic
acid, palmitoleic acid, oleic acid, and linoleic acid, but the structures have not been
determined or refined at this point. To obtain a complete picture of binding, these
structural approaches require binding affinity studies, as well as determination of whether
the different acids all behave the same as the cANGPTL4-palmitic acid complex with
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respect to fatty acid transport into the cell. This provides a self-contained project for a
future student. Additionally, crystals have been obtained of cANGPTL4 with added
fructose, glucose, and arabinose to investigate this protein’s ability to bind to other fuel
sources. The diffraction data has not yet been processed.
There is evidence to suggest that the binding of fatty acids may have other effects
as well, such as preventing the binding of other proteins. Previous studies have shown
that recombinant cANGPTL4 binds to integrin, claudin, and cadherin, serving to disrupt
cell-cell contacts and promoting metastasis. However, these studies were carried out with
the apoprotein, not liganded with fatty acids. Adding recombinant apoprotein to the cell
culture shows that it is bound to the cell surface, as would be expected on the basis of
results from a previous study (Huang et al., 2011). However, adding the holoprotein, a
cANGPTL4-fatty acid complex, to the cell culture does not show protein bound to the
cell surface but rather protein inside the cell, with the fatty acid still apparently bound.
To resolve these observations, the binding studies of Huang et al. would need to be
repeated using the cANGPTL4-fatty acid complex and compared to previous results to
determine if the bound fatty acid affects the proteins ability to bind to the three cell
surface proteins.
One concern was the role of glycosylation on cANGPTL4’s biological activity.
We carried out cell culture studies using immunofluorescence and confocal imaging.
These studies showed the same responses from endogenous protein as found when we
added recombinant, non-glycosylated, protein to the culture media. These are positive
results indicating that, for the scope of the questions probed in this dissertation,
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conclusions drawn on the basis of the recombinant protein are also valid for the
endogenously produced protein.
We were unable to express sufficient endogenous protein from cell culture to
attempt structural studies. The significant resources necessary to increase this production
were simply not available. Further, the three known binding partners are all integral
membrane proteins that are known to be glycosylated, considerably raising the difficulty
of carrying out classical crystallization and X-ray diffraction structural studies. An
approach using cryo-electron microscopy is potentially better suited to the complexes
with low abundance glycosylated integral membrane proteins and their low probability of
crystallization.

5.3 Conclusion
This research significantly expands our knowledge on the functional range of the
protein cANGPTL4 addressing the initial research goals. It has also opened up more
research questions that have been guided by the results produced. A total of three
structures were determined and deposited in the PDB consisting of glycerol, palmitic
acid, and myristic acid with cANGPTL4. This will enable others to explore these protein
complexes for the first time.
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Supplemental

Supplemental Figure 1: Autofluorescence was accessed by DIC imaging of Panc-1,
MiaPaCa2, Capan-1, MDA-MB231, MCF7, and SKBR3 cells. No autofluorescence was
detected in any of the cell lines. Scale bar = 100µm.
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Supplemental Figure 2: Protein analysis of recombinant human cANGPTL4. A) SDSPAGE with cANGPTL4. The strong band indicates successful expression and
purification of cANGPTL4. This protein is largely impurity free and well suited for
crystallization trials. B) Mass spectrometry analysis identified the amino acid sequence
of residues 185-400 of recombinant human ANGPTL4’s C-terminal domain.

102

